



PCT/GB 2003 / 000501
Rec'd PCT/PTO 22 JUL 2004

INVESTOR IN PEOPLE

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP23 5BQ

0800 08 MAY 2003

WIPO


PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



R. Mahoney

Signed

Dated 10 February 2003

BEST AVAILABLE COPY

An Executive Agency of the Department of Trade and Industry



The
Patent
Office

11FEB02 E694617-5 D02029
P01/7700 0.00-0203022.9

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

1. Your Reference

AP/PI4748

2. Patent application number

(The Patent office will fill in this part)

08 FEB 2002

0203022.9

3. Full name, address and postcode of the or of each applicant (underline all surnames)

GLAXO GROUP LIMITED
GLAXO WELLCOME HOUSE
BERKELEY AVENUE
GREENFORD
MIDDLESEX
UB6 ONN
GB

00473587003

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its corporation

GB

4 Title of the invention

CHEMICAL COMPOUNDS

5 Name of your agent (if you know one)

PETER I DOLTON

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

GLAXOSMITHKLINE
CORPORATE INTELLECTUAL PROPERTY
CN925.1
980 GREAT WEST ROAD
BRENTFORD
MIDDLESEX
TW8 9GS, GB

Patents ADP number (if you know it)

08321846001

6. If you are declaring priority from one or more earlier patent applications, give the country and date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)

Date of Filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant a patent required in support of this request? (Answer yes if:

YES

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an applicant, or
- c) any named applicant is a corporate body.

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form	-
Description	32
Claim(s)	3
Abstract	1
Drawing(s)	-

10. If you are also filing any of the following, state how many against each item

Priority Documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patent Form 9/77*)

Request for substantive examination (*Patent Form 10/77*)

Any other documents
(*please specify*)

11.

I/We request the grant of a patent on the basis of this application

P. I. Dolton

Signature PETER I DOLTON. 8 February 2002
AGENT FOR THE APPLICANTS

12. Name and daytime telephone number of person to contact in the United Kingdom

JEAN HARNEY
020 8047 4420

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication of communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the patent Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been received

a) Notes

If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.

b) Write your answers in capital letters using black ink or you may type them.

c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form

If you have answered "Yes" Patents Form 7/77 will need to be filed.

d) Once you have filled in the form you must remember to sign and date it.


e) For details of the fee and ways to pay please contact the Patent Office.

Chemical Compounds

The present invention relates to C-aryl piperidine derivatives, to processes for their preparation, to pharmaceutical compositions containing them and to their medical use.

In particular the invention relates to novel compounds which are potent and specific antagonists of tachykinins, including substance P and other neurokinins.

Thus the present invention provides compounds of formula (I)



wherein

R represents halogen or C₁₋₄ alkyl;

R₁ represents C₁₋₄ alkyl;

R₂ represents hydrogen or C₁₋₄ alkyl;

R₃ represents hydrogen, or C₁₋₄ alkyl;

R₄ represents trifluoromethyl, C₁₋₄ alkyl, C₁₋₄ alkoxy, trifluoromethoxy or halogen;

R₅ represents hydrogen, C₁₋₄ alkyl, C₃₋₇ cycloalkyl or S(O)₂R₆;

R₆ represents C₁₋₄ alkyl or C₃₋₇ cycloalkyl;

m is zero or an integer from 1 to 3;

n is an integer from 1 to 3;

p is an integer from 1 to 2;

X and Y are independently C(O) or CH₂;

provided that

i) X and Y are not both C(O) and

ii) when X and Y are both CH₂, R₅ is not hydrogen or C₁₋₄ alkyl ;

and pharmaceutically acceptable salts and solvates thereof.

Suitable pharmaceutically acceptable salts of the compounds of general formula (I) include acid addition salts formed with pharmaceutically acceptable organic or inorganic acids, for example hydrochlorides, hydrobromides, sulphates, alkyl- or arylsulphonates (e.g. methanesulphonates or p-toluenesulphonates), phosphates, acetates, citrates, succinates, tartrates, fumarates and maleates.

The solvates may, for example, be hydrates.



References hereinafter to a compound according to the invention include both compounds of formula (I) and their pharmaceutically acceptable acid addition salts together with pharmaceutically acceptable solvates.

5



Suitable pharmaceutical acceptable salts of the compounds of general formula (I) may be obtained in a crystalline form and/or in an amorphous form or as a mixture thereof.

10

It will be appreciated by those skilled in the art that the compounds of formula (I) contain at least two chiral centres (namely the carbon atoms shown as * in formula (I)) and these may be represented by the formulae (1a, 1b, 1c and 1d).



15



20

The wedge shaped bond indicates that the bond is above the plane of the paper and is referred to as β configuration. The broken bond indicates that the bond is below the plane of the paper and is in the α configuration.

25

In general, in the specific compounds named below the β configuration at the 2 position of piperidine ring corresponds to the R configuration and the β configuration at 4 position of piperidine ring corresponds to the S configuration. The α configuration at the 2 position of piperidine ring corresponds to the S configuration and the α configuration at 4 position of piperidine ring corresponds to the R configuration. The assignment of the R or S configuration at the 2 and the 4 positions have been made according to the rules of Cahn, Ingold and Prelog, *Experientia* 1956, 12, 81.

30

Further asymmetric carbon atoms are possible in the compound of formula (I). Thus, when R_2 and R_3 are not the same group, the compounds of formula (I) possess at least four asymmetric carbon atoms.

It is to be understood that all enantiomers and diastereoisomers and mixtures thereof are encompassed within the scope of the present invention.

The term C_{1-4} alkyl as used herein as a group or a part of the group refers to a straight or branched alkyl group containing from 1 to 4 carbon atoms; examples of such groups include methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl or tert butyl.

The term halogen refers to a fluorine, chlorine, bromine or iodine atom.

The term C_{3-7} cycloalkyl group means a non aromatic monocyclic hydrocarbon ring of 3 to 7 carbon atom such as, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl.

A preferred group of compounds of formula (I) are those in which the carbon atom at the 2-position of piperidine ring is in the β configuration.

When R represents halogen this is suitably chlorine or more preferably fluorine or when R is C_{1-4} alkyl this is suitably methyl or ethyl wherein m is zero or an integer from 1 to 2.

Suitable values for R_2 or R_3 include hydrogen, a methyl, an ethyl or a propyl group.

R is preferably a halogen (e.g. fluorine) and/or a C_{1-4} alkyl (e.g. methyl) group and m is preferably zero or an integer from 1 to 2.

R_1 is preferably a methyl group.

R_2 is preferably a hydrogen atom or a methyl group.

R_3 is preferably a hydrogen atom or a methyl group.

R_4 is preferably a trifluoromethyl group or halogen (i.e chlorine).

A preferred class of compounds of formula (I) are those wherein each R is independently a halogen (e.g. fluorine) or a C_{1-4} alkyl (e.g. methyl) group, wherein m is 0, 1 or 2. More preferably m is 1 or 2. Within this class those wherein R is at the 2 and/or 4 position in the phenyl ring are particularly preferred.

Compounds of formula (I), wherein n is 2, represent a preferred class of compounds and within this class the groups R_4 are preferably at the 3 and 5 position in the phenyl ring.

Preferred compounds according to the invention are:

2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(R)-(3-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid, (3,5-bis-trifluoromethyl-benzyl)-methylamide;

2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-(3-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid, (3,5-bis-trifluoromethyl-benzyl)-methylamide;

5 2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(R)-(4-methyl-3-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid, 1-(3,5-bis-trifluoromethyl-benzyl)-methylamide;

2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-(4-methyl-3-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid, 1-(3,5-bis-trifluoromethyl-benzyl)-methylamide;

10 2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-(4-methyl-3-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid, [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide;

2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(R)-(2-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methylamide;

2-(4-Fluoro-2-methyl-phenyl)-4-(S)-(2-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid, (3,5-bis-trifluoromethyl-benzyl)-methylamide;

15 2-(4-Fluoro-2-methyl-phenyl)-4-(S)-(2-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid, (3,5-bis-trifluoromethyl-benzyl)-methylamide;

2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-(2-oxo-4-methyl-piperazin-1-yl)-piperidine-1-carboxylic acid, (3,5-bis-trifluoromethyl-benzyl)-methylamide;

20 2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-(4-methyl-2-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid, [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide;

2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-(4-methyl-2-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid, [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide;

2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(R)-(4-cyclopropyl-3-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid, 1-(3,5-bis-trifluoromethyl-benzyl)-methylamide;

25 2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-(4-cyclopropyl-3-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid, 1-(3,5-bis-trifluoromethyl-benzyl)-methylamide;

4-(S)-[1-[(3,5-Bis-trifluoromethyl-benzyl)-methyl-carbamoyl]-2-(R)-(4-fluoro-2-methyl-phenyl)-piperidin-4-yl]-piperazine;

2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-(1-methanesulfonyl-piperazin-1-yl)-piperidine-1-carboxylic acid, 1-(3,5-bis-trifluoromethyl-benzyl)-methylamide;

30 2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-(1-methanesulfonyl-piperazin-1-yl)-piperidine-1-carboxylic acid, 1-[(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide;

and pharmaceutically acceptable salts and solvates thereof.

35 The compounds of the invention are antagonists of tachykinins, including substance P and other neurokinins, both in vitro and in vivo and are thus of use in the treatment of conditions mediated by tachykinins, including substance P and other neurokinins.

40 NK₁-receptor binding affinity has been determined in vitro by the compounds' ability to displace [3H] - substance P (SP) from recombinant human NK₁ receptors expressed in Chinese Hamster Ovary (CHO) cell membranes.

CHO cell membranes were prepared by using a modification of the method described by Dam T and Quirion R (Peptides, 7:855-864, 1986). Thus ligand binding was performed in 0.4 ml of 50 mM HEPES, pH 7.4, containing 3 mM MnCl₂, 0.02% BSA, 0.5 nM [³H]Substance P (30÷

56 Ci/mmol, Amersham), a final membrane concentration of 25 µg of protein/ml, and the test compounds. The incubation proceeded at room temperature for 40 min.. Non-specific binding was determined using excess of Substance P (1 µM) and represents about 6% of the total binding.

5 Compounds of the invention were further characterised in a functional assay for the determination of their inhibitory effect. Human-NK₁-CHO cells were stimulated with Substance P and the receptor activation was evaluated by measuring the accumulation of cytidinediphosphodiacylglycerol (CDP-DAG), which is the liponucleotide precursor of phosphatidylinositol diphosphate. CDP-DAG accumulates in the presence of Li⁺ as a
10 consequence of the receptor mediated activation of phospholipase C (PLC) (Godfrey, Biochem. J., 258:621-624, 1989). The method is described in detail by Ferraguti et al. (Mol. Cell. Neurosci., 5:269-276, 1994).

15 The action of the compounds of the invention at the NK₁ receptor may be determined by using conventional tests. Thus the ability to penetrate the central nervous system and to bind at the NK₁ receptor was demonstrated in vivo by their inhibitory effect on the change in the behaviour induced by intracerebroventricular applied substance P in the gerbil, according to the gerbil foot tapping model as described by Rupniak & Williams, Eur. J. of Pharmacol., 1994.

20 Compounds of the invention are useful in the treatment of CNS disorders. In particular they are useful in the treatment or prevention of major depressive disorders including bipolar depression, unipolar depression, single or recurrent major depressive episodes with or without psychotic features, catatonic features, melancholic features, atypical features or postpartum
25 onset, the treatment of anxiety and the treatment of panic disorders. Other mood disorders encompassed within the term major depressive disorders include dysthymic disorder with early or late onset and with or without atypical features, neurotic depression, post traumatic stress disorders and social phobia; dementia of the Alzheimer's type, with early or late onset, with depressed mood; vascular dementia with depressed mood; mood disorders induced by
30 alcohol, amphetamines, cocaine, hallucinogens, inhalants, opioids, phencyclidine, sedatives, hypnotics, anxiolytics and other substances; schizoaffective disorder of the depressed type; and adjustment disorder with depressed mood. Major depressive disorders may also result from a general medical condition including, but not limited to, myocardial infarction, diabetes, miscarriage or abortion, etc.

35 Compounds of the invention have also been found to exhibit anxiolytic activity in conventional tests. For example in marmoset human threat test (Costall et al., 1988).

40 Compounds of the invention are useful as analgesics. In particular they are useful in the treatment of traumatic pain such as postoperative pain; traumatic avulsion pain such as brachial plexus; chronic pain such as arthritic pain such as occurring in osteo-, rheumatoid or psoriatic arthritis; neuropathic pain such as post-herpetic neuralgia, trigeminal neuralgia, segmental or intercostal neuralgia, fibromyalgia, causalgia, peripheral neuropathy, diabetic neuropathy, chemotherapy-induced neuropathy, AIDS related neuropathy, occipital neuralgia, geniculate neuralgia, glossopharyngeal neuralgia, reflex sympathetic dystrophy, phantom

limb pain; various forms of headache such as migraine, acute or chronic tension headache, temporomandibular pain, maxillary sinus pain, cluster headache; odontalgia; cancer pain; pain of visceral origin; gastrointestinal pain; nerve entrapment pain; sport's injury pain; dysmennorrhoea; menstrual pain; meningitis; arachnoiditis; musculoskeletal pain; low back pain e.g. spinal stenosis; prolapsed disc; sciatica; angina; ankylosing spondylitis; gout; burns; scar pain; itch; and thalamic pain such as post stroke thalamic pain.

Compounds of the invention are also useful in the treatment of sleep disorders including dysomnia, insomnia, sleep apnea, narcolepsy, and circadian ritmic disorders.

Compounds of the invention are also useful in the treatment or prevention of the cognitive disorders. Cognitive disorders include dementia, amnesic disorders and cognitive disorders not otherwise specified.

Furthermore compounds of the invention are also useful as memory and/or cognition enhancers in healthy humans with no cognitive and/or memory deficit.

Compounds of the invention are also useful in the treatment of tolerance to and dependence on a number of substances. For example, they are useful in the treatment of dependence on nicotine, alcohol, caffeine, phencyclidine (phencyclidine like compounds), or in the treatment of tolerance to and dependence on opiates (e.g cannabis, heroin, morphine) or benzodiazepines; in the treatment of cocaine, sedative ipnotic, amphetamine or amphetamine-related drugs (e.g dextroamphetamine, methylamphetamine) addiction or a combination thereof.

Compounds of the invention are also useful as anti-inflammatory agents. In particular they are useful in the treatment of inflammation in asthma, influenza, chronic bronchitis and rheumatoid arthritis; in the treatment of inflammatory diseases of the gastrointestinal tract such as Crohn's disease, ulcerative colitis, inflammatory bowel disease and non-steroidal anti-inflammatory drug induced damage; inflammatory diseases of the skin such as herpes and eczema; inflammatory diseases of the bladder such as cystitis and urge incontinence; and eye and dental inflammation.

Compounds of the invention are also useful in the treatment of allergic disorders, in particular allergic disorders of the skin such as urticaria, and allergic disorders of the airways such as rhinitis.

Compounds of the invention are also useful in the treatment of emesis, i.e. nausea, retching and vomiting. Emesis includes acute emesis, delayed emesis and anticipatory emesis. The compounds of the invention are useful in the treatment of emesis however induced. For example, emesis may be induced by drugs such as cancer chemotherapeutic agents such as alkylating agents, e.g. cyclophosphamide, carmustine, lomustine and chlorambucil; cytotoxic antibiotics, e.g. dactinomycin, doxorubicin, mitomycin-C and bleomycin; anti-metabolites, e.g. cytarabine, methotrexate and 5- fluorouracil; vinca alkaloids, e.g. etoposide, vinblastine

and vincristine; and others such as cisplatin, dacarbazine, procarbazine and hydroxyurea; and combinations thereof; radiation sickness; radiation therapy, e.g. irradiation of the thorax or abdomen, such as in the treatment of cancer; poisons; toxins such as toxins caused by metabolic disorders or by infection, e.g. gastritis, or released during bacterial or viral gastrointestinal infection; pregnancy; vestibular disorders, such as motion sickness, vertigo, dizziness and Meniere's disease; post-operative sickness; gastrointestinal obstruction; reduced gastrointestinal motility; visceral pain, e.g. myocardial infarction or peritonitis; migraine; increased intracranial pressure; decreased intracranial pressure (e.g. altitude sickness); opioid analgesics, such as morphine; and gastro-oesophageal reflux disease, acid indigestion, over-indulgence of food or drink, acid stomach, sour stomach, waterbrash/regurgitation, heartburn, such as episodic heartburn, nocturnal heartburn, and meal-induced heartburn and dyspepsia.

Compounds of the invention are also useful in the treatment of gastrointestinal disorders such as irritable bowel syndrome; skin disorders such as psoriasis, pruritis and sunburn; vasospastic diseases such as angina, vascular headache and Reynaud's disease; cerebral ischaemia such as cerebral vasospasm following subarachnoid haemorrhage; fibrosing and collagen diseases such as scleroderma and eosinophilic fasciitis; disorders related to immune enhancement or suppression such as systemic lupus erythematosus and rheumatic diseases such as fibrositis; and cough.

Compounds of the invention are of particular use in the treatment of depressive states, in the treatment of anxiety and of panic disorders.

Depressive states include major depressive disorders including bipolar depression, unipolar depression, single or recurrent major depressive episodes with or without psychotic features, catatonic features, melancholic features, atypical features or postpartum onset, dysthymic disorder with early or late onset and with or without atypical features, neurotic depression and social phobia; dementia of the Alzheimer's type, with early or late onset, with depressed mood; vascular dementia with depressed mood; mood disorders induced by alcohol, amphetamines, cocaine, hallucinogens, inhalants, opioids, phencyclidine, sedatives, hypnotics, anxiolytics and other substances; schizoaffective disorder of the depressed type.

Compounds of the invention may be administered in combination with other active substances such as 5HT₃ antagonists, serotonin agonists, selective serotonin reuptake inhibitors (SSRI), noradrenaline re-uptake inhibitors (SNRI), tricyclic antidepressants or dopaminergic antidepressants.

Suitable 5HT₃ antagonists which may be used in combination of the compounds of the inventions include for example ondansetron, granisetron and metoclopramide.

Suitable serotonin agonists which may be used in combination with the compounds of the invention include sumatriptan, rauwolscine, yohimbine and metoclopramide.

Suitable SSRI which may be used in combination with the compounds of the invention include fluoxetine, citalopram, femoxetine, fluvoxamine, paroxetine, indalpine, sertraline and zimeldine.

- 5 Suitable SNRI which may be used in combination with the compounds of the invention include venlafaxine and reboxetine.

Suitable tricyclic antidepressants which may be used in combination with a compound of the invention include imipramine, amitriptyline, chlomipramine and nortriptyline.

- 10 Suitable dopaminergic antidepressants which may be used in combination with a compound of the invention include bupropion and amineptine.

- 15 It will be appreciated that the compounds of the combination or composition may be administered simultaneously (either in the same or different pharmaceutical formulations) or sequentially.

The invention therefore provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof for use in therapy, in particular in human medicine.

- 20 There is also provided as a further aspect of the invention the use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof in the preparation of a medicament for use in the treatment of conditions mediated by tachykinins, including substance P and other neurokinins.

- 25 In an alternative or further aspect there is provided a method for the treatment of a mammal, including man, in particular in the treatment of conditions mediated by tachykinins, including substance P and other neurokinins, comprising administration of an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.

- 30 It will be appreciated that reference to treatment is intended to include prophylaxis as well as the alleviation of established symptoms. Compounds of formula (I) may be administered as the raw chemical but the active ingredient is preferably presented as a pharmaceutical formulation.

- 35 Accordingly, the invention also provides a pharmaceutical composition which comprises at least one compound of formula (I) or a pharmaceutically acceptable salt thereof and formulated for administration by any convenient route. Such compositions are preferably in a form adapted for use in medicine, in particular human medicine, and can conveniently be
40 formulated in a conventional manner using one or more pharmaceutically acceptable carriers or excipients.

Thus compounds of formula (I) may be formulated for oral, buccal, parenteral, topical (including ophthalmic and nasal), depot or rectal administration or in a form suitable for administration by inhalation or insufflation (either through the mouth or nose).

5 For oral administration, the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g. lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g. magnesium stearate, talc or silica); disintegrants (e.g. potato starch or sodium starch glycollate); or wetting agents (e.g. sodium lauryl sulphate).
10 The tablets may be coated by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically
15 acceptable additives such as suspending agents (e.g. sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g. lecithin or acacia); non-aqueous vehicles (e.g. almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (e.g. methyl or propyl-p-hydroxybenzoates or sorbic acid). The preparations may also contain buffer salts, flavouring, colouring and sweetening agents as appropriate.

20 Preparations for oral administration may be suitably formulated to give controlled release of the active compound.

For buccal administration the composition may take the form of tablets or lozenges
25 formulated in conventional manner.

The compounds of the invention may be formulated for parenteral administration by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form e.g. in ampoules or in multi-dose containers, with an added preservative. The
30 compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile pyrogen-free water, before use.

35 The compounds of the invention may be formulated for topical administration in the form of ointments, creams, gels, lotions, pessaries, aerosols or drops (e.g. eye, ear or nose drops). Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents. Ointments for administration to the eye may be manufactured in a sterile manner using sterilised components.

40 Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilising agents, dispersing agents, suspending agents, thickening agents, or colouring agents. Drops may be formulated with an aqueous or non-

aqueous base also comprising one or more dispersing agents, stabilising agents, solubilising agents or suspending agents. They may also contain a preservative.

- 5 The compounds of the invention may also be formulated in rectal compositions such as suppositories or retention enemas, e.g. containing conventional suppository bases such as cocoa butter or other glycerides.



- 10 The compounds of the invention may also be formulated as depot preparations. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds of the invention may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

- 15 For intranasal administration, the compounds of the invention may be formulated as solutions for administration via a suitable metered or unitary dose device or alternatively as a powder mix with a suitable carrier for administration using a suitable delivery device.

- 20 A proposed dose of the compounds of the invention is 1 to about 1000mg per day. It will be appreciated that it may be necessary to make routine variations to the dosage, depending on the age and condition of the patient and the precise dosage will be ultimately at the discretion of the attendant physician or veterinarian. The dosage will also depend on the route of administration and the particular compound selected.



- 25 Compounds of formula (I), and salts and solvates thereof, may be prepared by the general methods outlined hereinafter. In the following description, the groups R, R₁, R₂, R₃, R₄, R₅, R₆, m, n and p, have the meaning as previously defined for compounds of formula (I) unless otherwise stated.

- 30 Compounds of formula (I), wherein X is CH₂ or C(O) and Y is CH₂, may be prepared by reductive N-alkylation of a compound of formula (II),




with a piperazine derivative (III) in an aprotic solvent such as dichloroethane and in the presence of a suitable metal reducing agent such as sodium borohydride or sodium triacetoxyborohydride.

- 5 Compounds of formula (II) may be prepared by treating compounds of formula (IV)




- 10 with triphosgene in an aprotic solvent such as dichloromethane and in the presence of an organic base such triethylamine to form the intermediate carbonyl chloride compound (V) which may be isolated if required, followed by reaction of compound (V) with the amine compound (VI)



The reaction conveniently takes place in an aprotic solvent such as a hydrocarbon, a halohydrocarbon such as dichloromethane or an ether such as tetrahydrofuran optionally in the presence of a base such as a tertiary amine e.g. diisopropylethylamine.

Compounds of formula (I), wherein Y is C(O), may be prepared by cyclisation of a compound of formula(VII), wherein P is nitrogen protecting group, L is a suitable leaving group (i.e chlorine or bromine),



(VII)

following by removal of any protecting group.

The cyclisation reaction takes place in an aprotic solvent such as dichloromethane at a temperature ranging from 0° to 25° C.

- 5 Where it is desired to isolate a compound formula (I) as a salt, for example a pharmaceutically acceptable salt, this may be achieved by reacting the compound of formula (I) in the form of the free base with an appropriate amount of suitable acid and in a suitable solvent such as an alcohol (e.g. ethanol or methanol), an ester (e.g. ethyl acetate) or an ether (e.g. diethyl ether or tetrahydrofuran).

10

Pharmaceutically acceptable salts may also be prepared from other salts, including other pharmaceutically acceptable salts, of the compounds of formula (I) using conventional methods.

- 15 Compounds of formula (IV), (V) and (VI) may be prepared by analogous methods to those used for known compounds.

- 20 Compound of formula (I) may be converted into other compound of formula (I). Thus compounds of formula (I) wherein R₅ is S(O)₂R₆ can be prepared by reaction of a compound of formula (I) wherein R₅ is hydrogen with L-S(O)₂R₆, wherein L is a suitable leaving group (i.e chlorine or bromine).

25

The compounds of formula (I) may readily be isolated in association with solvent molecules by crystallisation from or evaporation of an appropriate solvent to give the corresponding solvates.

When a specific enantiomer of a compound of general formula (I) is required, this may be obtained for example by resolution of a corresponding enantiomeric mixture of a compound of formula (I) using conventional methods.

- 30 Thus, for example, specific enantiomers of the compounds of formula (I) may be obtained from the corresponding enantiomeric mixture of a compound of formula (I) using chiral HPLC procedure.

Alternatively, enantiomers of a compound of general formula (I) may be synthesised from the appropriate optically active intermediates using any of the general processes described herein.

Thus for example the required enantiomer may be prepared by the corresponding a chiral piperidin-4-one of formula (IV) using the process described above for preparing compounds of formula (I) from compounds (IV), followed by separation of the diastereomeric mixture of a compound of formula(I) using conventional procedure.

The chiral compounds (IV) may be prepared from the corresponding racemic compound (IV) using conventional procedures such as salt formation with a suitable optically active acid, separating the resultant diastereoisomeric salts by conventional means e.g. chromatography and crystallisation followed by hydrolysis of the diastereoisomeric salts.

A suitable optically active acid for use in the process is L(+)-mandelic acid.

In a further embodiment of the invention the chiral compound (IV) may be prepared using Comins reaction as described in Journal American Chemical Society 1994,116, 4719-4728, followed by reduction of 2,3 dihydro-1H-pyridin-4-one derivative to piperidin-4-one derivative. The reduction may be effected using hydrogen and metal catalyst e.g. palladium on a suitable support e.g. carbon or alumina. The reaction is carried out in a solvent such as ester e.g. ethyl acetate.

In a further embodiment of the invention the enantiomers of the compound of formula (I) may be prepared by reaction of a chiral amine (VI) using any of the processes described above for preparing compounds of formula (I) from amine (V).

The chiral amine (III) may be prepared from the corresponding racemic amine (III) using any conventional procedures such as salt formation with a suitable optically active acid.

The invention is further illustrated by the following Intermediates and Examples which are not intended as a limitation of the invention. In the Intermediates and Examples unless otherwise stated:

In the Intermediates and Examples unless otherwise stated:

Melting points (m.p.) were determined on a a Büchi 530 melting point apparatus and are uncorrected. All temperatures refers to °C. Infrared spectra were measured on a FT-IR instrument. ¹H-NMR spectra were recorded on Varian instruments at 400 or 500 MHz, chemical shifts are reported in ppm (δ) using the residual solvent line as internal standard. The signals are assigned as singlets (s), doublets (d), doublets of doublets (dd), triplets (t), quartets (q) or multiplets (m). Mass spectra were taken on a VG Quattro mass spectrometer. Flash column chromatography was carried out over silica gel (Merck AG Darmstadt, Germany). Optical rotations were determined at 20°C with a Jasco DIP360 instrument (l = 10 cm, cell volume = 1 mL, λ= 589nm). The following abbreviations are used in the text: AcOEt = ethyl acetate, CH = cyclohexane, DCM = dichloromethane, Et₂O = diethyl ether, DMF = N,N'-dimethylformamide, DIPEA=N,N-diisopropylethylamine, MeOH = methanol, TEA = triethylamine, TFA = trifluoroacetic

acid, THF = tetrahydrofuran. T.l.c. refers to thin layer chromatography on 0.25 mm silica plates (60F-254 Merck) and dried refers to solution dried over anhydrous sodium sulphate; r.t. (RT) refers to room temperature.

5 Intermediate 1

1-(Benzyloxycarbonyl)-2-(4-fluoro-2-methyl-phenyl)-2,3-dihydro-4-pyridone

A small amount of iodine was added to a suspension of magnesium turnings (13.2 g) in dry THF (300 mL), at r.t., under a nitrogen atmosphere, then the mixture was vigorously refluxed for 20 minutes. To this suspension, a 15% of a solution of 2-bromo-5-fluoro-toluene (52.5 mL) in anhydrous THF (300 mL) was added. The suspension was heated under vigorous reflux until the brown colour disappeared. The remaining part of the bromide solution was added drop-wise over 1 hour to the refluxing suspension which was then stirred for a further 1 hour. This solution of Grignard reagent was then added drop-wise to the pyridinium salt obtained from benzyl chloroformate (48.7 mL) and 4-methoxypyridine (25 mL) in dry THF (900 mL) at -23°C.

The obtained solution was stirred 1 hour at -20°C then it was warmed up to 20°C, a 10% hydrochloric acid solution (560 mL) was added and the aqueous layer was extracted with AcOEt (2 x 750 mL).

The combined organic extracts were washed with 5% sodium hydrogen carbonate solution (600 mL) and brine (600 mL) then partially concentrated *in vacuo*.

CH (400 mL) was added drop-wise over 1 hour at 20°C and the resulting mixture was stirred 30 minutes and then filtered to give the title compound as a white solid (66 g).

IR (nujol, cm⁻¹): 1726 and 1655 (C=O), 1608 (C=C).

NMR (d₆-DMSO): δ (ppm) 8.19 (d, 1H); 7.31-7.18 (m, 5H); 7.08 (m, 2H); 6.94 (dt, 1H); 5.77 (d, 1H); 5.36 (d, 1H); 5.16 (2d, 2H); 3.26 (dd, 1H); 2.32 (d, 1H); 2.26 (s, 3H).

MS (ES/+): m/z=340 [MH]⁺.

Intermediate 2

2-(4-Fluoro-2-methyl-phenyl)-piperidine-4-one

30 Method A

2-Methyl-4-fluoro-benzaldehyde (4 g) was added to a solution of 4-aminobutan-2-one ethylene acetal (3.8 g) in dry benzene (50 mL) and the solution was stirred at r.t. under a nitrogen atmosphere. After 1 hour the mixture was heated at reflux for 16 hours and then allowed to cool to r.t. This solution was slowly added to a refluxing solution of p-toluensulphonic acid (10.6 g) in dry benzene (50 mL) previously refluxed for 1 hour with a Dean-Stark apparatus. After 3.5 hours the crude solution was cooled and made basic with a saturated potassium carbonate solution and taken up with AcOEt (50 mL). The aqueous phase was extracted with AcOEt (3 x 50 mL) and Et₂O (2 x 50 mL). The organic layer was dried and concentrated *in vacuo* to a yellow thick oil as residue (7.23 g). A portion of the crude mixture (3 g) was dissolved in a 6N hydrochloric acid solution (20 mL) and stirred at 60°C for 16 hours. The solution was basified with solid potassium carbonate and extracted with DCM (5 x 50 mL). The combined organic phases were washed with brine (50 mL), dried and concentrated *in vacuo* to give the title compound (2.5 g) as a thick yellow oil.

Method B

L-selectride (1M solution in dry THF, 210 mL) was added drop-wise, over 80 minutes, to a solution of intermediate 1 (50 g) in dry THF (1065 mL) previously cooled to -72°C under a nitrogen atmosphere. After 45 minutes, 2% sodium hydrogen carbonate solution (994 mL) was added drop-wise and the solution was extracted with AcOEt (3 x 994 mL). The combined organic phases were washed with water (284 mL) and brine (568 mL). The organic phase was dried and concentrated *in vacuo* to get 1-benzyloxycarbonyl-2-(4-fluoro-2-methyl-phenyl)-piperidine-4-one as a pale yellow thick oil (94 g) which was used as a crude.

This material (94 g) was dissolved in AcOEt (710 mL), then 10% Pd/C (30.5 g) was added under a nitrogen atmosphere. The slurry was hydrogenated at 1 atmosphere for 30 minutes. The mixture was filtered through Celite and the organic phase was concentrated *in vacuo* to give the crude 2-(4-fluoro-2-methyl-phenyl)-piperidine-4-one as a yellow oil. This material was dissolved in AcOEt (518 mL) at r.t. and racemic camphorsulphonic acid (48.3 g) was added. The mixture was stirred at r.t for 18 hours, then the solid was filtered off, washed with AcOEt (2 x 50 mL) and dried *in vacuo* for 18 hours to give 2-(4-fluoro-2-methyl-phenyl)-piperidine-4-one, 10-camphorsulfonic acid salt as a pale yellow solid (68.5 g). (M.p.: 167-169°C - NMR (d_6 -DMSO): δ (ppm) 9.43 (bs, 1H); 9.23 (bs, 1H); 7.66 (dd, 1H); 7.19 (m, 2H); 4.97 (bd, 1H); 3.6 (m, 2H); 2.87 (m, 3H); 2.66 (m, 1H); 2.53 (m, 2H); 2.37 (s + d, 4H); 2.22 (m, 1H); 1.93 (t, 1H); 1.8 (m, 2H); 1.26 (m, 2H); 1.03 (s, 3H); 0.73 (s, 3H).

This material (68.5 g) was suspended in AcOEt (480 mL) and stirred with a saturated sodium hydrogen carbonate (274 mL). The organic layer was separated and washed with further water (274 mL). The organic phase was dried and concentrated *in vacuo* to give the title compound (31 g) as a yellow-orange oil.

NMR (d_6 -DMSO): δ (ppm) 7.49 (dd, 1H); 7.00 (m, 2H); 3.97 (dd, 1H); 3.27 (m, 1H); 2.82 (dt, 1H); 2.72 (bm, 1H); 2.47 (m, 1H); 2.40 (m, 1H); 2.29 (s, 3H); 2.25 (dt, 1H); 2.18 (m, 1H). MS (ES/+): m/z =208 [MH]⁺.

Intermediate 3**2-(4-Fluoro-2-methyl-phenyl)-4-oxo-piperidine-1-carboxylic acid, (3,5-bis-trifluoromethyl-benzyl)-methylamide.**

A solution of triphosgene (1.43 g) dissolved in dry DCM (10 mL) was added to a solution of intermediate 2 (2.5 g) and DIPEA (8.4 mL) in dry DCM (20 mL) previously cooled to 0°C under a nitrogen atmosphere. The solution was stirred at 0°C for 2 hours, then (3,5-bis-trifluoromethyl-benzyl)-methylamine hydrochloride (5.63 g) and DIPEA (3.34 mL) were added. The mixture was stirred under nitrogen at r. t. for 14 hours. The mixture was taken up with AcOEt (50 mL), washed with cold 1N hydrochloric acid solution (3 x 20 mL) and brine (10 mL). The organic layer was dried and concentrated *in vacuo* to a residue which was purified by flash chromatography (AcOEt/CH 3:7) to give the title compound as a white foam (3.85 g).

IR (nujol, cm^{-1}): 1721 and 1641 (C=O).

NMR (d_6 -DMSO): δ (ppm) 7.96 (s, 1H); 7.76 (s, 2H); 7.25 (dd, 1H); 6.97 (dd, 1H); 6.90 (dt, 1H); 5.22 (t, 1H); 4.59 (d, 1H); 4.43 (d, 1H); 3.63-3.49 (m, 2H); 2.79 (s, 3H); 2.69 (m, 2H); 2.49 (m, 2H); 2.26 (s, 3H).

MS (ES/+): m/z = 491 [MH]⁺.

Intermediate 4

2-(R)-(4-Fluoro-2-methyl-phenyl)-4-oxo-piperidine-1-carboxylic acid, [1-(R)-3,5-bis-trifluoromethyl-phenyl]-ethyl]-methylamide (4a) and

5 **2-(S)-(4-Fluoro-2-methyl-phenyl)-4-oxo-piperidine-1-carboxylic acid, [1-(R)-3,5-bis-trifluoromethyl-phenyl]-ethyl]-methylamide (4b)**

Method A

10 A solution of triphosgene (147 mg) dissolved in dry DCM (5 mL) was added drop-wise to a solution of intermediate 2 (250 mg) and DIPEA (860 μ L) in dry DCM (15 mL) previously cooled to 0°C under a nitrogen atmosphere. After 2 hours, [1-(R)-3,5-bis-trifluoromethyl-phenyl]-ethyl]-methylamine hydrochloride (503 mg) and DIPEA (320 μ L) in dry acetonitrile (20 mL) were added and the mixture was heated to 70°C for 16 hours. Further [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamine hydrochloride (170 mg) and DIPEA (100 μ L) were added and the mixture was stirred at 70°C for further 4 hours. Next, the mixture
15 was allowed to cool to r.t., taken up with AcOEt (30 mL), washed with a 1N hydrochloric acid cold solution (3 x 15 mL) and brine (2 x 10 mL). The organic layer was dried and concentrated *in vacuo* to a residue, which was purified by flash chromatography (CH/AcOEt 8:2) to give:

1. intermediate 4a (230 mg) as a white foam,
- 20 2. intermediate 4b (231 mg) as a white foam.

Intermediate 4a

NMR (d_6 -DMSO): δ (ppm) 7.98 (bs, 1H); 7.77 (bs, 2H); 7.24 (dd, 1H); 6.97 (dd, 1H); 6.89 (m, 1H); 5.24 (t, 1H); 5.14 (q, 1H); 3.61 (m, 1H); 3.55 (m, 1H); 2.71 (m, 2H); 2.56 (s, 3H); 2.50 (m, 2H); 2.26 (s, 3H); 1.57 (d, 3H).

Intermediate 4b

25 NMR (d_6 -DMSO): δ (ppm) 7.96 (bs, 1H); 7.75 (bs, 2H); 7.24 (dd, 1H); 6.98 (dd, 1H); 6.93 (dt, 1H); 5.29 (q, 1H); 5.24 (t, 1H); 3.56 (m, 1H); 3.48 (m, 1H); 2.70 (s, 3H); 2.50 (m, 4H); 2.26 (s, 3H); 1.54 (d, 3H).

Intermediate 4a**Method B**

30 A saturated sodium hydrogen carbonate solution (324 mL) was added to a solution of intermediate 9 (21.6 g) in AcOEt (324 mL) and the resulting mixture was vigorously stirred for 15 minutes. The aqueous layer was back-extracted with further AcOEt (216 mL) and the combined organic extracts were dried and concentrated *in vacuo* to give intermediate 8 as a
35 yellow oil, which was treated with TEA (19 mL) and AcOEt (114 mL). The solution obtained was added drop-wise over 40 minutes to a solution of triphosgene (8 g) in AcOEt (64 mL) previously cooled to 0°C under a nitrogen atmosphere, maintaining the temperature between 0°C and 8°C.

40 After stirring for 1 hours at 0°C and for 3 hours at 20°C, [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamine hydrochloride (29.7 g), AcOEt (190 mL) and TEA (38 mL) were added to the reaction mixture which was then heated to reflux for 16 hours.

The solution was washed with 10% sodium hydroxide solution (180 mL), 1% hydrochloric acid solution (4 x 150 mL), water (3 x 180 mL) and brine (180 mL). The organic layer was

dried and concentrated *in vacuo* to a residue, which was purified through a silica pad (CH/AcOEt 9:1) to give the title compound (21.5 g) as a brown thick oil.

NMR (d_6 -DMSO): δ (ppm) 7.97-7.77 (bs + bs, 3H); 7.24 (dd, 1H); 6.97 (dd, 1H); 6.88 (td, 1H); 5.24 (m, 1H); 5.14 (q, 1H); 3.58 (m, 2H); 2.7 (m, 2H); 2.56 (s, 3H); 2.49 (m, 2H); 2.26 (s, 3H); 1.57 (d, 3H).

Intermediate 5

2-(S)-(4-Fluoro-2-methyl-phenyl)-4-oxo-piperidine-1-carboxylic acid, [1-(S)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide (5a) and

2-(R)-(4-Fluoro-2-methyl-phenyl)-4-oxo-piperidine-1-carboxylic acid, [1-(S)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide (5b)

A solution of triphosgene (147 mg) dissolved in dry DCM (5 mL) was added to a solution of intermediate 2 (250 mg) and DIPEA (860 μ L) in dry DCM (15 mL) previously cooled to 0°C under a nitrogen atmosphere. After 2 hours, a solution of [1-(S)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamine hydrochloride (510 mg) and DIPEA (320 μ L) in dry acetonitrile (20 mL) was added and the mixture was heated to 70°C for 16 hours. Next, further [1-(S)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamine hydrochloride (170 mg) and DIPEA (105 μ L) were added. After further 4 hours at 70°C, the mixture was allowed to cool to r.t., taken up with AcOEt (30 mL), washed with a 1N hydrochloric acid cold solution (3 x 15 mL) and brine (2 x 10 mL). The organic layer was dried and concentrated *in vacuo* to a residue, which was purified by flash chromatography (CH/AcOEt 8:2) to give:

1. intermediate 5a (234 mg) as a white foam,
2. intermediate 5b (244 mg) as a white foam.

Intermediate 5a

NMR (d_6 -DMSO): δ (ppm) 7.97-7.77 (bs + bs, 3H); 7.24 (dd, 1H); 6.97 (dd, 1H); 6.88 (td, 1H); 5.24 (m, 1H); 5.14 (q, 1H); 3.58 (m, 2H); 2.7 (m, 2H); 2.56 (s, 3H); 2.49 (m, 2H); 2.26 (s, 3H); 1.57 (d, 3H).

Intermediate 5b

NMR (d_6 -DMSO): δ (ppm) 7.98 (bs, 1H); 7.77 (bs, 2H); 7.24 (dd, 1H); 6.97 (dd, 1H); 6.89 (m, 1H); 5.24 (t, 1H); 5.14 (q, 1H); 3.61 (m, 1H); 3.55 (m, 1H); 2.71 (m, 2H); 2.56 (s, 3H); 2.50 (m, 2H); 2.26 (s, 3H); 1.57 (d, 3H).

Intermediate 6

2-(S)-(4-Fluoro-2-methyl-phenyl)-4-oxo-3,4-dihydro-2H-pyridine-1-carboxylic acid, (1R, 2S, 5R)-2-isopropyl-5-methyl-cyclohexyl ester (6a) and

2-(R)-(4-Fluoro-2-methyl-phenyl)-4-oxo-3,4-dihydro-2H-pyridine-1-carboxylic acid, (1R, 2S, 5R)-2-isopropyl-5-methyl-cyclohexyl ester (6b)

A solution of 2-bromo-5-fluoro-toluene (3.68 g) in dry THF (10 mL) was dropped over 30 minutes, into a mixture of magnesium (525 mg) and iodine (1 crystal) in dry THF (5 mL) previously heated to 70°C under a nitrogen atmosphere. The mixture was stirred at 70°C for 1.5 hours, then allowed to cool to r.t..

A solution of (-)-mentyl chloroformate (3.53 mL) in dry THF (15 mL) was added to a solution of 4-methoxypyridine (1.52 mL) in dry THF (35 mL) previously cooled to -78°C under a nitrogen atmosphere. After 15 minutes, the solution containing the 4-fluoro-2-methyl-

phenyl magnesium bromide was added drop-wise, and the mixture was stirred at -78°C for 1 hour. The reaction was quenched by the addition of 1M hydrochloric acid solution (20 mL), warmed to r.t. and stirred at 23°C for 30 minutes. After extraction with AcOEt (2 x 150 mL), the combined organic extracts were washed with brine (50 mL), dried and concentrated *in vacuo* to a residue, which was purified by flash chromatography (CH/THF/toluene 8:1:1) to give:

1. intermediate **6a** (3.44g - yellow oil)
2. intermediate **6b** (530 mg- white solid).

Intermediate 6a

10 T.l.c.: CH/THF/toluene 7:2:1, $R_f=0.59$.

IR (nujol, cm^{-1}): 1718 and 1675 ($\text{C}=\text{O}$).

NMR (d_6 -DMSO): δ (ppm) 8.14 (d, 1H); 7.08 (dd, 1H); 7.02 (dd, 1H); 6.95 (m, 1H); 5.68 (d, 1H); 5.34 (d, 1H); 4.47 (m, 1H); 3.26 (dd, 1H); 2.30 (m, 4H); 1.7 (m, 4H); 1.33 (m, 2H); 0.8 (m, 11H).

15 Intermediate 6b

M.p.: $117-120^{\circ}\text{C}$.

T.l.c.: CH/THF/toluene 7:2:1, $R_f=0.56$.

IR (nujol, cm^{-1}): 1718 and 1669 ($\text{C}=\text{O}$).

20 NMR (d_6 -DMSO): δ (ppm) 8.17 (d, 1H); 7.04-6.94 (m, 3H); 5.70 (d, 1H); 5.35 (d, 1H); 4.42 (m, 1H); 3.26 (dd, 1H); 2.30 (m, 4H); 1.58-1.40 (m, 3H); 1.2-0.7 (m, 8H); 0.51-0.34 (bs, 6H):

Intermediate 7

2-(R)-(4-Fluoro-2-methyl-phenyl)-2,3-dihydro-1H-pyridin-4-one

25 Sodium methoxide (100 mg) was added to a solution of intermediate **6b** (170 mg) in MeOH (15 mL) under a nitrogen atmosphere. The mixture was refluxed for two hours, and the solvent was removed *in vacuo*. The residue was partitioned between water (10 mL) and AcOEt (15 mL). The layers were separated, and the aqueous phase was extracted with further AcOEt (4 x 10 mL). The combined organic extracts were washed with brine (10 mL), dried and concentrated *in vacuo* to give the title compound (145 mg) as a light yellow oil.

30 NMR (d_6 -DMSO): δ (ppm) 7.71 (bd, 1H); 7.45 (dd, 1H); 7.38 (t, 1H); 7.03 (m, 2H); 4.86 (dd, 1H); 4.77 (d, 1H); 2.42 (dd, 1H); 2.31 (m, 4H).

MS (ES/+): $m/z=206$ $[\text{M}+\text{H}]^+$.

Intermediate 8

2-(R)-(4-Fluoro-2-methyl-phenyl)-piperidin-4-one

35 Palladium over charcoal (10% - 74 mg) was added to a solution of intermediate **7** (145 mg) in MeOH (8 mL) and THF (2 mL). The mixture was allowed to react with hydrogen in a pressure reactor (2 atm) overnight. After flushing with nitrogen, the solution was filtered and the solvent removed *in vacuo*. The crude product was purified by flash chromatography (AcOEt/MeOH 9:1) to give the title compound (26 mg) as a yellow oil.

40 The enantiomeric excess (90-95%) was detected by chiral HPLC.

T.l.c.: AcOEt/MeOH 9:1, $R_f=0.2$.

NMR (d_6 -DMSO): δ (ppm) 7.49 (dd, 1H); 7.00 (m, 2H); 3.97 (dd, 1H); 3.27 (m, 1H); 2.82 (dt, 1H); 2.72 (bm, 1H); 2.47 (m, 1H); 2.40 (m, 1H); 2.29 (s, 3H); 2.25 (dt, 1H); 2.18 (m, 1H).

MS (ES/+): $m/z=208$ $[MH]^+$.
[α]_D = +82.1 (c=1.07, DMSO).

Intermediate 9

5 2-(R)-(4-Fluoro-2-methyl-phenyl)-piperidin-4-one mandelic acid

A solution of L-(+)-mandelic acid (22.6 g) in AcOEt (308 mL) was added to a solution of intermediate 2 (31 g) in AcOEt (308 mL). Then isopropanol (616 mL) was added and the solution was concentrated *in vacuo* to 274 mL. The solution was then cooled to 0°C and further cold isopropanol (96 mL) was added. The thick precipitate was stirred under nitrogen
10 for 5 hours at 0°C, then filtered and washed with cold Et₂O (250 mL) to give the title compound as a pale yellow solid (20.3 g).

M.p.: 82-85°C.

NMR (d₆-DMSO): δ (ppm) 7.51 (dd, 1H); 7.40 (m, 2H); 7.32 (m, 2H); 7.26 (m, 1H); 7.0 (m, 2H); 4.95 (s, 1H); 4.04 (dd, 1H); 3.31 (m, 1H); 2.88 (m, 1H); 2.49-2.2 (m, 4H); 2.29 (s, 3H).

15 Chiral HPLC: HP 1100 HPLC system; column Chiralcel OD-H, 25 cm x 4.6 mm; mobile phase: n-hexane/isopropanol 95:5 + 1% diethylamine; flow: 1.3 mL/min; detection: 240/215nm; retention time 12.07 minutes.

Intermediate 10

20 2-(R)-4-Fluoro-2-methyl-phenyl)-4-oxo-piperidine-1-carboxylic acid, (3,5-bis-trifluoromethyl-benzyl)-methylamide

Method A

A solution of triphosgene (17 mg) in dry DCM (2 mL) was added to a solution of intermediate 8 (26 mg) and DIPEA (65 mg) in dry DCM (3 mL) previously cooled to 0°C
25 under a nitrogen atmosphere. After two hours acetonitrile (10 mL) was added, the temperature was allowed to reach r.t. and the DCM evaporated under a nitrogen flush. Then, a solution of 3,5-(bis-trifluoromethyl-benzyl)-methylamine hydrochloride (74 mg) and DIPEA (130 mg) in acetonitrile (3 mL) was added and the mixture was stirred at 23°C overnight. The solvent was concentrated *in vacuo*. The residue was dissolved in AcOEt (10 mL) and washed
30 with 1N hydrochloric acid solution (3 x 5 mL), 5% sodium hydrogen carbonate (5 mL) and brine (10 mL). The organic layer was dried and concentrated *in vacuo* to a residue, which was purified by flash chromatography (CH₂Cl₂/AcOEt 1:1) to give the title compound (50 mg) as a white solid.

Method B

35 A saturated sodium hydrogen carbonate solution (348 mL) was added to a solution of intermediate 9 (23.2 g) in AcOEt (348 mL) and the resulting mixture was vigorously stirred for 15 minutes. The aqueous layer was back-extracted with further AcOEt (230 mL) and the combined organic extracts were dried and concentrated *in vacuo* to give intermediate 8 (12.31 g) as a yellow oil, which was treated with TEA (20.5 mL) and AcOEt (123 mL). The solution
40 obtained was added drop-wise over 40 minutes to a solution of triphosgene (8 g) in AcOEt (61 mL) previously cooled to 0°C under a nitrogen atmosphere, maintaining the temperature between 0°C and 8°C.

After stirring for 2 hours at 20°C, 3,5-(bis-trifluoromethyl-benzyl)-methylaniline hydrochloride (28.1 g), AcOEt (184 mL) and TEA (33 mL) were added to the reaction mixture which was then further stirred for 2 hours at 20°C.

The solution was washed with 10% sodium hydroxide solution (3 x 185 mL) and 1% hydrochloric acid solution (3 x 185 mL). The organic layer was dried and concentrated *in vacuo* to a crude (38 g), which was purified through a silica pad (CH/AcOEt from 9:1 to 1:1) to give the title compound (24.7 g) as a colourless oil.

NMR (d_6 -DMSO): δ (ppm) 7.96 (s, 1H); 7.76 (s, 2H); 7.26 (dd, 1H); 6.98 (dd, 1H); 6.90 (td, 1H); 5.23 (t, 1H); 4.61 (d, 1H); 4.41 (d, 1H); 3.60 (m, 2H); 2.69 (m, 2H); 2.79 (s, 3H); 2.50 (m, 2H); 2.27 (s, 3H).

MS (ES/+): m/z =491 [MH]⁺.

Intermediate 11

3-Oxo-piperazine-1-carboxylic acid *tert*-butyl ester

Di-*tert*-butyl-dicarbonate (647 mg) and TEA (0.937 mL) were added to a solution of 2-oxo-piperazine (267 mg) in DCM (30 mL) under a nitrogen atmosphere. The mixture was stirred for 4 hours at r.t., then concentrated *in vacuo* to a residue which was purified by flash chromatography (AcOEt/MeOH 8:2) to give the title compound (355 mg) as a white solid.

T.l.c.: AcOEt/MeOH 8:2, R_f=0.14.

IR (nujol, cm⁻¹): 3412 (NH), 1677 (C=O).

NMR (d_6 -DMSO): δ (ppm) 6.40 (bs, 1H); 4.10 (dd, 2H); 3.64 (t, 2H); 3.39 (m, 2H); 1.48 (s, 9H).

MS (ES/+): m/z =201 [M+H-HCl]⁺, 223 [M-HCl+Na]⁺, 145 [M+H-*t*Bu+H]⁺.

Intermediate 12

4-Methyl-3-oxo-piperazine-1-carboxylic acid *tert*-butyl ester

Sodium hydride (60 % suspension in oil, 105 mg) was added to a solution intermediate 11 (351 mg) in anhydrous THF (30 mL) and DMF (6 mL) under a nitrogen atmosphere. The mixture was stirred at r.t. for 1 hour, then iodomethane (0.218 mL) was added. The solution was warmed at 80°C for 3 hours, then was cooled to r.t. and a saturated ammonium chloride solution was added. The organic layer was washed with iced water (20 mL) and brine (20 mL). The solution was concentrated *in vacuo* to give the title compound (195 mg) as a yellow oil.

T.l.c.: AcOEt/MeOH/TEA 80:20:1, R_f=0.51.

NMR (CDCl₃): δ (ppm) 4.05 (s, 2H); 3.65 (m, 2H); 3.30 (m, 2H); 1.45 (m, 9H).

Intermediate 13

{2-[1-(3,5-Bis-trifluoromethyl-benzyl)-methyl-carbamoyl]-2-(R)-(4-fluoro-2-methyl-phenyl)-piperidin-4-(R)-yl-amino]-ethyl}-carbamic acid, *tert*-butyl ester (13a) and

{2-[1-(3,5-Bis-trifluoromethyl-benzyl)-methyl-carbamoyl]-2-(R)-(4-fluoro-2-methyl-phenyl)-piperidin-4-(S)-yl-amino]-ethyl}-carbamic acid, *tert*-butyl ester (13b)

N-BOC-ethylenediamine (0.109 mL) was added to a solution of intermediate 10 (152 mg) in dry 1,2-dichloroethane (3 mL) and dry acetonitrile (3 mL) under a nitrogen atmosphere. The mixture was stirred at 23°C for 16 hour, then sodium triacetoxyborohydride (98 mg) was

added and the solution was stirred at 23°C for 6 hours. The solution was washed with a 5% sodium hydrogen carbonate solution (10 mL) and brine (10 mL). The organic layer was dried and concentrated *in vacuo* to a residue which was purified by flash chromatography (AcOEt/MeOH 8:2) to give two fractions:

1. intermediate 13a (65 mg)
2. intermediate 13b (39 mg)

Intermediate 13a:

T.l.c.: AcOEt/MeOH 8:2, Rf=0.41.

NMR (d_6 -DMSO): δ (ppm) 7.91 (bs, 1H); 7.62 (bs, 2H); 7.21 (dd, 1H); 6.87 (dd, 1H); 6.67 (m, 1H); 6.71 (bt, 1H); 4.63 (m, 1H); 4.53 (d, 1H); 4.35 (d, 1H); 3.3-2.8 (m, 5H); 2.83 (s, 3H); 2.51 (bm, 2H); 2.25 (s, 3H); 1.90-1.45 (m, 4H); 1.33 (s, 9H).

MS (ES/+): m/z =635 $[MH]^+$, 579 $[M-tBu+H]^+$.

Intermediate 13b:

T.l.c.: AcOEt/MeOH 8:2, Rf=0.25.

NMR (d_6 -DMSO): δ (ppm) 7.90 (bs 1H); 7.55 (bs 2H); 7.16 (dd, 1H); 6.85 (dd, 1H); 6.73 (m, 1H); 6.64 (bt, 1H); 4.58 (d, 1H); 4.31 (d, 1H); 4.09 (dd, 1H); 3.37 (m, 1H); 2.91 (m, 2H); 2.87 (s, 3H); 2.64 (m, 1H); 2.52 (m, 3H); 2.30 (s, 3H); 1.89 (m, 2H); 1.82 (m, 2H); 1.31 (s, 9H).

MS (ES/+): m/z =635 $[MH]^+$, 579 $[M-tBu+H]^+$.

Intermediate 14

{2-[1-{{1-(R)-(3,5-Bis-trifluoromethyl-phenyl)-ethyl}-methyl-carbamoyl}-2-(R)-(4-fluoro-2-methyl-phenyl)-piperidin-4-(R)-yl-amino]-ethyl}-carbamic acid, *tert*-butyl ester (14a) and

{2-[1-{{1-(R)-(3,5-Bis-trifluoromethyl-phenyl)-ethyl}-methyl-carbamoyl}-2-(R)-(4-fluoro-2-methyl-phenyl)-piperidin-4-(S)-yl-amino]-ethyl}-carbamic acid, *tert*-butyl ester (14b)

N-BOC-ethylenediamine (0.435 ml) was added to a solution of intermediate 4a (462 mg) in dry 1,2-dichloroethane (9 mL) and dry acetonitrile (9 mL) under a nitrogen atmosphere. The mixture was stirred at 23°C for 30 minutes, then sodium triacetoxyborohydride (298 mg) was added. The solution was stirred at 23°C for 16 hours, then washed with a 5% sodium hydrogen carbonate solution (10 mL) and brine (10 mL). The organic layer was dried and concentrated *in vacuo* to a residue which was purified by flash chromatography (AcOEt/MeOH 9:1) to give two fractions.

1. intermediate 14a (252 mg - T.l.c.: AcOEt/MeOH 8:2 Rf=0.42).

2. intermediate 14b (116 mg - T.l.c.: AcOEt/MeOH 8:2 Rf=0.34).

Intermediate 14a:

NMR (d_6 -DMSO): δ (ppm) 7.98 (bs, 1H); 7.71 (bs, 2H); 7.23 (dd, 1H); 6.92 (dd, 1H); 6.80 (dt, 1H); 6.74 (bt, 1H); 5.22 (q, 1H); 4.73 (dd, 1H); 3.27 (m, 1H); 3.09 (m, 1H); 3.01 (m, 2H); 2.87 (m, 2H); 2.66 (s, 3H); 2.52 (m, 2H); 2.28 (s, 3H); 1.87 (m, 1H); 1.80 (bs, 1H); 1.65 (m, 2H); 1.49 (m, 4H); 1.37 (s, 9H).

MS (ES/+): m/z =649 $[M+H]^+$; 593 $[M-tBu+H]^+$, 549 $[M+H-BOC+H]^+$.

Intermediate 14b:

NMR (d_6 -DMSO): δ (ppm) 7.99 (s, 1H); 7.68 (s, 2H); 7.14 (dd, 1H); 6.90 (dd, 1H); 6.76 (dt, 1H); 6.70 (bs, 1H); 5.31 (m, 1H); 4.13 (dd, 1H); 3.3 (m, 2H); 2.97 (m, 3H); 2.72 (s, 3H); 2.59 (bs, 2H); 2.34 (s, 3H); 1.8-1.4 (bm, 5H); 1.46 (d, 3H); 1.36 (s, 9H).

MS (ES/+): m/z =649 $[M+H]^+$, 593 $[M-tBu+H]^+$.

5

Intermediate 15

(2-Cyclopropylamino-ethyl)-carbamic acid, tert-butyl ester

Cyclopropylamine (866 μ L) was added to a solution of tert-butyl-N-(2-oxo-ethyl)carbamate (1 g) in MeOH (50 mL) under a nitrogen atmosphere. The resulting solution was stirred at 23°C for 1 hour, then potassium borohydride (372 mg) was added and the mixture was stirred at 23°C for a further 1 hour. The mixture was concentrated to half volume, diluted with a saturated sodium hydrogen carbonate solution (20 mL) and extracted with AcOEt (2 x 30 mL). The combined organic extracts were dried, concentrated *in vacuo* to a residue, which was purified by flash chromatography (AcOEt/MeOH 9:1) to give the title compound (1.22 g) as a yellow oil.

NMR (CDCl₃): δ (ppm) 8.25 (bm, 1H); 3.2 (dd, 2H); 2.8 (dd, 2H); 2.1 (m, 1H); 1.42 (s, 9H); 0.42 (dd, 2H); 0.29 (m, 2H).

MS (ES/+): m/z =201 $[M+H]^+$, 145 $[M-tBu]^+$.

20 Intermediate 16

{2-[(2-Bromoacetyl)-cyclopropyl-amino]-ethyl}carbamic acid, tert-butyl ester

TEA (719 μ L) and bromoacetyl bromide (0.27 μ L) were added to a solution of intermediate 15 (511 mg) in anhydrous DCM (25 mL) previously cooled to 0°C under a Nitrogen atmosphere. The solution was stirred at 0°C for 30 minutes, then it was quenched with brine (15 mL). The layers were separated and the organic phase was dried and concentrated *in vacuo*. The residue was purified by flash chromatography (CH₂Cl₂/AcOEt 65:35) to give the title compound (394 mg) as a yellow solid.

T.l.c.: CH₂Cl₂/AcOEt 1:1, R_f=0.43 (detection only with ninhydrin).

NMR (CDCl₃): δ (ppm) 4.85 (bm, 1H); 4.1 (s, 2H); 3.5 (m, 2H); 3.3 (m, 2H); 2.88 (m, 1H); 1.42 (s, 9H); 0.95 (m, 2H); 0.85 (m, 2H).

Intermediate 17

4-Cyclopropyl-3-oxo-piperazine-1-carboxylic acid, tert-butyl ester

Sodium hydride (60% dispersion in mineral oil – 147 mg) was added to a solution of intermediate 16 (394 mg) in anhydrous THF (12 mL) and DMF (12 mL) previously cooled to 0°C under a Nitrogen atmosphere. The mixture was stirred at 0°C for 1.5 hours, then water (20 mL) was added and the mixture was extracted with AcOEt (3 x 30 mL). The combined organic extracts were washed with cold water (20 mL) and brine (20 mL), dried and concentrated *in vacuo*. The residue was purified by flash chromatography (CH₂Cl₂/AcOEt 1:1) to give the title compound (210 mg) as a yellow oil.

T.l.c.: CH₂Cl₂/AcOEt 1:1, R_f=0.23 (detection only with ninhydrin).

NMR (CDCl₃): δ (ppm) 5.5 (m, 2H); 4.0 (s, 2H); 3.23 (m, 2H); 2.7 (m, 1H); 1.42 (s, 9H); 0.8 (m, 2H); 0.65 (m, 2H).

Intermediate 18

4-(R)-[1-[(3,5-Bis-trifluoromethyl-benzyl)-methyl-carbamoyl]-2-(R)-(4-fluoro-2-methyl-phenyl)-piperidin-4-yl]-piperazine-1-carboxylic acid, *tert*-butyl ester (18a) and

4-(S)-[1-[(3,5-Bis-trifluoromethyl-benzyl)-methyl-carbamoyl]-2-(R)-(4-fluoro-2-methyl-phenyl)-piperidin-4-yl]-piperazine-1-carboxylic acid, *tert*-butyl ester (18b)

- 5 A solution of intermediate 10 (400 mg) and N-*tert*-butoxycarbonyl-piperazine (151.8 mg) in dry 1,2-dichloroethane (10 mL) was stirred at r.t. for 30 minutes under a nitrogen atmosphere. Then, sodium triacetoxymethylborohydride (310 mg) was added and the mixture was stirred at 23°C for 24 hours. The solution was diluted with AcOEt and washed with water. The organic layer
10 was dried and concentrated *in vacuo* to a residue, which was purified by flash chromatography (AcOEt/MeOH from 9:1) to give:
intermediate 18a (181 mg),
intermediate 18b (155 mg).

Intermediate 18a:

- 15 T.l.c.: AcOEt/MeOH 8:2, R_f=0.35.
IR (nujol, cm⁻¹): 1703 and 1651 (C=O).
NMR (d₆-DMSO): δ (ppm) 7.91 (s, 1H); 7.65 (s, 2H); 7.26 (dd, 1H); 6.89 (dd, 1H); 6.79 (bt, 1H); 4.78 (dd, 1H); 4.52 (d, 1H); 4.37 (d, 1H); 3.25 (m, 6H); 3.09 (m, 1H); 2.78 (s, 3H); 2.37 (bs, 4H); 2.22 (s, 3H); 1.86 (m, 1H); 1.78 (m, 1H); 1.68 (m, 2H); 1.35 (s, 9H).
20 MS (ES/+): m/z=661 [MH]⁺.

Intermediate 18b

- T.l.c.: AcOEt/MeOH 8:2, R_f=0.14.
IR (nujol, cm⁻¹): 1702 and 1654 (C=O).
NMR (d₆-DMSO): δ (ppm) 7.90 (s, 1H); 7.56 (s, 2H); 7.18 (dd, 1H); 6.85 (dd, 1H); 6.73 (dt, 1H); 4.59 (d, 1H); 4.32 (d, 1H); 4.1 (dd, 1H); 3.41 (bm, 1H); 3.21 (bs, 4H); 2.87 (s, 3H); 2.64 (t, 1H); 2.5 (m, 1H); 2.39 (bs, 4H); 2.3 (s, 3H); 1.82 (bs, 1H); 1.73 (m, 1H); 1.56 (dq, 1H); 1.33 (s, 9H); 1.33 (q, 1H).
25 MS (ES/+): m/z=661 [MH]⁺.

30 **Examples 1a and 1b**

2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(R)-(3-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid, (3,5-bis-trifluoromethyl-benzyl)-methylamide

(Example 1a)

2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-(3-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid, (3,5-bis-trifluoromethyl-benzyl)-methylamide

35 **(Example 1b)**

- Piperazin-2-one (60 mg) was added to a solution of intermediate 10 (150 mg) in dry 1,2-dichloroethane (3 mL) and dry acetonitrile (3 mL) under a Nitrogen atmosphere. The mixture was stirred at 23°C for 16 hour, then sodium triacetoxymethylborohydride (97 mg) was added. The solution was stirred at 23°C for 6 hours, then washed with a 5% sodium hydrogen carbonate solution (10 mL) and brine (10 mL). The organic layer was dried and concentrated *in vacuo* to a residue which was purified by flash chromatography (AcOEt/MeOH 9:1) to give two fractions:
- 40

1. example 1a (23 mg - T.l.c.: AcOEt/MeOH 8:2 R_f=0.24)

2. example 1b (56 mg - T.l.c.: AcOEt/MeOH 8:2 Rf=0.11).

Example 1a:

IR (nujol, cm^{-1}): 3350 (NH^+), 1734 and 1635 ($\text{C}=\text{O}$).

NMR (d_6 -DMSO): δ (ppm) 7.94 (s, 1H); 7.78 (s, 1H); 7.66 (s, 2H); 7.30 (m, 1H); 6.93 (dd, 1H); 6.83 (m, 1H); 4.75 (dd, 1H); 4.58 (d, 1H); 4.40 (d, 1H); 3.3 (m, 2H); 3.10-3.00 (m, 4H); 3.83 (s, 3H); 2.70-2.50 (m, 3H); 2.27 (s, 3H); 2.00-1.60 (m, 4H).

MS (ES/+): $m/z=575$ $[\text{M}+\text{H}]^+$.

Example 1b:

IR (nujol, cm^{-1}): 3213 (NH^+), 1737 and 1657 ($\text{C}=\text{O}$).

NMR (d_6 -DMSO): δ (ppm) 7.94 (s, 1H); 7.66 (s, 1H); 7.59 (s, 2H); 7.25 (dd, 1H); 6.89 (dd, 1H); 6.77 (m, 1H); 4.62 (d, 1H); 4.37 (d, 1H); 4.14 (dd, 1H); 3.46-3.04 (m, 4H); 2.90 (s, 3H); 1.88-1.36 (m, 4H).

MS (ES/+): $m/z=575$ $[\text{M}+\text{H}]^+$.

Example 2

2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(R)-(3-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid, (3,5-bis-trifluoromethyl-benzyl)-methylamide hydrochloride

Hydrochloric acid (1M in Et_2O – 0.3 mL) was added to a solution of example 1a (23 mg) in dry Et_2O (3 mL) previously cooled to 0°C under a nitrogen atmosphere. The resulting solution was stirred at 0°C for 30 minutes, then it was concentrated *in vacuo* to give the title compound (18 mg) as a white solid.

NMR (d_6 -DMSO): δ (ppm) 10.87 (bs, 1H); 8.46 (bs, 1H); 7.81 (s, 1H); 7.79 (s, 2H); 7.36 (m, 1H); 6.97 (m, 2H); 4.49 (q, 2H); 3.87-3.13 (bm, 9H); 2.76 (s, 3H); 2.25 (s, 3H); 2-0.5 (m, 4H).

MS (ES/+): $m/z=575$ $[\text{M}+\text{H}-\text{HCl}]^+$, 597 $[\text{M}-\text{HCl}+\text{Na}]^+$.

Example 3

2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-(3-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid, (3,5-bis-trifluoromethyl-benzyl)-methylamide hydrochloride

Hydrochloric acid (1M in Et_2O – 0.5 mL) was added to a solution of example 1b (56 mg) in dry Et_2O (5 mL) previously cooled to 0°C under a nitrogen atmosphere. The resulting solution was stirred at 0°C for 30 minutes, then it was concentrated *in vacuo* to give the title compound (46 mg) as a white solid.

IR (nujol, cm^{-1}): 3421 (NH^+), 1676 ($\text{C}=\text{O}$).

NMR (d_6 -DMSO): δ (ppm) 10.84 (bs, 1H); 8.41 (s, 1H); 7.95 (s, 1H); 7.59 (s, 1H); 7.28 (m, 1H); 6.92 (dd, 1H); 6.82 (m, 1H); 4.62 (d, 1H); 4.37 (d, 1H); 4.19 (dd, 1H); 3.9-3.2 (m, 7H); 2.82 (s, 3H); 2.75 (m, 1H); 2.37 (s, 3H); 2.25-2.7, (m, 4H).

MS (ES/+): $m/z=575$ $[\text{M}+\text{H}-\text{HCl}]^+$, 597 $[\text{M}-\text{HCl}+\text{Na}]^+$.

Examples 4a and 4b

2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(R)-(4-methyl-3-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid, 1-(3,5-bis-trifluoromethyl-benzyl)-methylamide (4a)

2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-(4-methyl-3-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid, 1-(3,5-bis-trifluoromethyl-benzyl)-methylamide (4b)

TFA (0.8 mL) was added to a solution of intermediate **12** (190 mg) in DCM (8 mL) previously cooled to 0°C under a nitrogen atmosphere. The mixture was stirred at r.t. for 4 hours, then it was concentrated *in vacuo* to give 1-methyl-piperazin-2-one trifluoroacetate (102 mg) which was used as a crude in the following reactions.

- 5 1-Methyl-piperazin-2-one trifluoroacetate (102 mg) and TEA (0.185 mL) were added to a solution of intermediate **10** (217 mg) in dry dichloroethane (6 mL) and dry acetonitrile (6 mL) under a nitrogen atmosphere. The mixture was stirred at 23°C for 16 hours, then sodium triacetoxyborohydride (281 mg) was added and the solution was stirred for 6 hours. The mixture was washed with a 5 % sodium hydrogen carbonate solution (10 mL) and brine (10 mL). The organic layer was dried and concentrated *in vacuo*, to a residue which was purified by flash chromatography (AcOEt/MeOH 9:1) to give two fractions:

1. example **4a** (56 mg - T.l.c.: AcOEt/MeOH 8:2, R_f=0.33),
2. example **4b** (42 mg - T.l.c.: AcOEt/MeOH 8:2, R_f=0.13).

Example 4a

- 15 IR (nujol, cm⁻¹): 1649 (C=O).

NMR (d₆-DMSO): δ (ppm) 7.95 (bs, 1H); 7.66 (bs, 2H); 7.22; (dd, 1H); 6.93 (dd, 1H); 6.83 (dt, 1H); 4.72 (dd, 1H); 4.58 (d, 1H); 4.39 (d, 1H); 3.3-3.1 (m, 2H); 3.9-2.6 (m, 1H); 2.53 (m, 4H); 3.09 (m, 2H); 2.84 (s, 3H); 2.83 (s, 3H); 2.28 (s, 3H); 1.95-1.65 (m, 4H).

MS (ES/+): m/z=589 [M+H]⁺.

- 20 **Example 4b:**

IR (nujol, cm⁻¹): 1650 (C=O).

NMR (d₆-DMSO): δ (ppm) 7.94 (bs, 1H); 7.59 (bs, 2H); 7.24 (dd, 1H); 6.90 (dd, 1H); 6.77 (dt, 1H); 4.62 (d, 1H); 4.37 (d, 1H); 4.13 (dd, 1H); 3.46 (m, 1H); 3.20 (m, 2H); 3.10 (m, 2H); 2.91 (s, 3H); 2.78 (s, 3H); 2.80-2.50 (m, 4H); 2.35 (s, 3H); 1.89 (m, 1H); 1.83 (m, 1H); 1.61 (m, 1H); 1.34 (q, 1H).

MS (ES/+): m/z=589 [M+H]⁺, 611 [M+Na]⁺.

Example 5

- 30 **2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(R)-(4-methyl-3-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid, 1-(3,5-bis-trifluoromethyl-benzyl)-methylamide hydrochloride**

A solution of example **4a** (56 mg) in dry Et₂O (5 mL) was treated with hydrochloric acid (1M in Et₂O – 0.5 mL) and the resulting solution was stirred at 23°C for 30 minutes. The solution was concentrated *in vacuo* to give the title compound as a white solid (26 mg).

IR (nujol, cm⁻¹): 1653 (C=O).

- 35 NMR (d₆-DMSO): δ (ppm) 11.10 (bs, 1H); 7.95 (s, 1H); 7.59 (s, 2H); 7.27 (bt, 1H); 6.93 (d, 1H); 6.82 (bt, 1H); 4.62 (d, 1H); 4.37, (d, 1H); 4.37 (d, 1H); 4.18 (d, 1H); 3.95-3.25 (m, 7H); 2.93 (s, 3H); 2.86 (s, 3H); 2.72 (t, 1H); 2.37 (s, 3H); 2.20-2.08 (m, 2H); 1.90 (bm 1H); 1.8-1.6 (bm, 1H).

MS (ES/+): m/z=589 [MH-HCl]⁺, 611 [M-HCl+Na]⁺.

40

Example 6

2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-(4-methyl-3-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid, 1-(3,5-bis-trifluoromethyl-benzyl)-methylamide hydrochloride

A solution of example 4b (42 mg) in dry Et₂O (4 mL) was treated with hydrochloric acid (1M in Et₂O – 0.4 mL) and the resulting solution was stirred at 23°C for 30 minutes. The solution was concentrated *in vacuo* to give the title compound (28 mg) as a white solid.

IR (nujol, cm⁻¹): 3395 (NH⁺), 2800-2500 (NH⁺), 1665 (C=O), 1623 (C=C).

5 NMR (d₆-DMSO): δ (ppm) 10.93 (bs, 1H); 7.98 (bs, 1H); 7.78 (bs, 2H); 7.36 (bm, 1H); 7.01 (bm, 1H); 6.92 (bm, 1H); 5.19 (bm, 1H); 4.59 (d, 1H); 4.41 (d, 1H); 4.1-3 (bm, 9H); 2.89 (s, 3H); 2.76 (s, 3H); 2.5-2.0 (bm, 6H); 1.80 (bm, 1H).

MS (ES/+): m/z=589 [MH-HCl]⁺.

10 Example 7

2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-(4-methyl-3-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid, [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide hydrochloride

15 TFA (1 mL) was added to a solution of intermediate 12 (210 mg) in DCM (9 mL) previously cooled to 0°C under a nitrogen atmosphere. The mixture was stirred at r.t. for 4 hours, then was concentrated *in vacuo* to give 1-methyl-piperazin-2-one trifluoroacetate (210 mg) which was dissolved in DCM (10 mL) and the mixture treated with solid potassium carbonate. The inorganic material was filtered off and the solution was concentrated *in vacuo* to give 1-methyl-piperazin-2-one (111 mg). The residue was added to a solution intermediate 4b (245
20 mg) in dry 1,2-dichloroethane (4 mL) and dry acetonitrile (4 mL) under a nitrogen atmosphere. The mixture was stirred at 23°C for 16 hours, then sodium triacetoxyborohydride (354 mg) was added. The solution was stirred at 23°C for 3 days, then washed with a 5% sodium hydrogen carbonate solution (10 mL) and brine (10 mL). The organic layer was dried and concentrated *in vacuo* to a residue which was purified by flash chromatography
25 (AcOEt/MeOH 98:2) to give three fractions:

1. diastereoisomer 1 (C-2 and C-4 anti configuration - 9 mg - T.l.c.: AcOEt/MeOH 9:1, R_f=0.27).
2. mixture of the two diastereoisomers (104 mg).
3. diastereoisomer 2 (C-2 and C-4 syn configuration - 24 mg - T.l.c.: AcOEt/MeOH 9:1,
30 R_f=0.22).

A solution of diastereoisomer 2 (24 mg) in dry Et₂O (1 mL) was treated with hydrochloric acid (1M in Et₂O – 0.2 mL). The resulting solution was stirred at 0°C for 30 minutes, then it was concentrated *in vacuo* to give the title compound (13 mg) as a white solid.

35 NMR (d₆-DMSO, 70°C): δ (ppm) 11 (bs, 1H); 7.92 (s, 1H); 7.67 (s, 2H); 7.23 (dd, 1H); 6.90 (dd, 1H); 6.79 (m, 1H); 5.32 (q, 1H); 4.21 (dd, 1H); 3.5-2.8 (m, 9H); 2.10 (m, 2H); 1.8 (m, 1H); 1.7 (m, 1H); 2.86 (s, 3H); 2.74 (s, 3H); 2.37 (s, 3H); 1.47 (d, 3H).

MS (ES/+): m/z=603 [M+H-HCl]⁺.

Example 8

40 2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(R)-(2-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methylamide hydrochloride

Bromoacetyl bromide (5 μL) and TEA (13 μL) were added to a solution of intermediate 13a (29 mg) in dry DCM (0.5 mL) previously cooled to 0°C under a nitrogen atmosphere. The solution was stirred at 0°C for 30 minutes, then it was washed with brine. The organic layer

was dried and concentrated *in vacuo* to give {2-[1-(3,5-bis-trifluoromethyl-benzyl)-methyl-carbamoyl]-2-(R)-(4-fluoro-2-methyl-phenyl)-piperidin-4-(R)-yl]-2-bromo-acetyl)-amino-ethyl}-carbamic acid, *tert*-butyl ester (28 mg), which was used without further purification in the next reactions.

- 5 TFA (0.1 mL) was added to a solution of this material (28 mg) in dry DCM (0.9 mL), previously cooled to 0°C under a nitrogen atmosphere. The mixture was stirred at 23°C for 1 hour. The organic layer was washed with a saturated solution of sodium hydrogen carbonate (1 mL) and brine (1 mL), then dried. After concentration *in vacuo*, the residue was purified by flash chromatography (AcOEt/MeOH 9:1) to give of 2-(R)-(4-fluoro-2-methyl-phenyl)-4-(R)-
10 (2-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid, (3,5-bis-trifluoromethyl-benzyl)-methylamide (11 mg).

This material (11 mg) was dissolved in dry Et₂O (1 mL) and treated with hydrochloric acid (1M in Et₂O – 0.1 mL). The resulting solution was stirred at 23°C for 30 minutes, then concentrated *in vacuo* to give the title compound (6 mg) as a white solid.

- 15 NMR (d₆-DMSO): δ (ppm) 9.19 (bs, 2H); 8.00 (s, 1H); 7.88 (s, 2H); 5.75 (m, 1H); 7.24-6.98 (m, 1H); 5.31 (bs, 1H); 4.8 (bs, 1H); 4.56 (d, 1H); 4.46 (d, 1H); 3.6 (m, 1H); 3.4 (m, 6H); 3.00 (m, 1H); 2.73 (s, 3H); 2.16 (s, 3H); 2.1 (m, 1H); 1.9 (m, 1H); 1.6 (m, 2H).
MS (ES/+): m/z=575 [M+H-HCl]⁺.

20 Example 9

2-(4-Fluoro-2-methyl-phenyl)-4-(S)-(2-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid, (3,5-bis-trifluoromethyl-benzyl)-methylamide

- Bromoacetyl bromide (7 µL) and TEA (18 µL) were added to a solution of intermediate 13b (41 mg) in dry DCM (0.6 mL) previously cooled to 0°C under a nitrogen atmosphere. The
25 solution was stirred at 0°C for 30 minutes. The organic layer was washed with brine, dried and concentrated *in vacuo* to give {2-[1-(3,5-bis trifluoromethyl-benzyl)-methyl-carbamoyl]-2-(R)-(4-fluoro-2-methyl-phenyl)-piperidin-4-(S)-yl]-2-bromo-acetyl)-amino-ethyl}-carbamic acid, *tert*-butyl ester (19 mg), which was used without further purification for the next reaction.

- 30 TFA (0.05 mL) was added to a solution of this material (18 mg) in dry DCM (0.45 mL), previously cooled to 0°C under a nitrogen atmosphere. The mixture was stirred at 23°C for 1 hour. The organic layer was washed with a saturated solution of sodium hydrogen carbonate (1 mL) and brine (1 mL), then dried. The residue was purified by flash chromatography (AcOEt/MeOH 8:2) to give the title compound (5.5 mg) as a white foam.

- 35 MS (ES/+): m/z=575 [M+H]⁺.

Example 10

2-(4-Fluoro-2-methyl-phenyl)-4-(S)-(2-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid, (3,5-bis-trifluoromethyl-benzyl)-methylamide hydrochloride

- 40 Hydrochloric acid (1M in Et₂O – 0.05 mL) was added to a solution of example 9 (5.5 mg) in dry Et₂O (0.5 mL) previously cooled to 0°C under a nitrogen atmosphere. The resulting solution was stirred at 0°C for 30 minutes, then concentrated *in vacuo* to give the title compound (3 mg) as a white solid.

NMR (d_6 -DMSO): δ (ppm) 9.19 (bs, 2H); 8.0 (s, 1H); 7.88 (s, 2H); 5.75 (m, 1H); 7.24-6.98 (m, 1H); 5.31 (bs, 1H); 4.8 (bs, 1H); 4.56 (d, 1H); 4.46 (d, 1H); 3.6 (m, 1H); 3.4 (m, 6H); 3.0 (m, 1H); 2.73 (s, 3H); 2.16 (s, 3H); 2.1 (m, 1H); 1.9 (m, 1H); 1.6 (m, 2H).

MS (ES/+): m/z =575 $[M+H-HCl]^+$.

5

Example 11

2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-(2-oxo-4-methyl-piperazin-1-yl)-piperidine-1-carboxylic acid, (3,5-bis-trifluoromethyl-benzyl)-methylamide

Formaldehyde (37 % in water, 0.093 mL) was added to a solution example 9 (270 mg) in 1,2-dichloroethane (4 mL). The mixture was stirred for 15 minutes at room temperature, then sodium triacetoxyborohydride (149 mg) was added. The solution was stirred for 3 hours at 23°C, then it was washed with 5% sodium hydrogen carbonate solution (10 mL) and brine. The organic layer was dried and concentrated *in vacuo* to a residue which was purified by flash chromatography (AcOEt/MeOH 8:2) to give 2-(R)-(4-fluoro-2-methyl-phenyl)-4-(S)-(2-oxo-4-methyl-piperazin-1-yl)-piperidine-1-carboxylic acid, (3,5-bis-trifluoromethyl-benzyl)-methylamide (120 mg).

This material (120 mg) was dissolved in dry Et₂O (2 mL) and treated with hydrochloric acid (1M in Et₂O – 0.4 mL). The resulting solution was stirred at 0°C for 30 minutes, then it was concentrated *in vacuo* to give the title compound (90 mg) as a white solid.

IR (nujol, cm⁻¹): 1653 (C=O).

NMR (d_6 -DMSO): δ (ppm) 10.6 (bs, 1H); 7.95 (s, 1H); 7.60 (2.25, 2H); 7.28 (dd, 1H); 6.92 (dd, 1H); 6.80 (t, 1H); 4.64 (d, 1H); 4.44 (t, 1H); 4.38 (d, 1H); 4.23 (dd, 1H); 4-3.2 (bm, 5H); 2.92 (s, 3H); 2.8 (m, 2H); 2.9-2.5 (sb, 3H); 2.34 (s, 3H); 1.98 (m, 2H); 1.75-1.55 (m, 2H).

MS (ES/+): m/z =589 $[M+H-HCl]^+$.

25

Example 12

2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-(4-methyl-2-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid, [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide

Bromoacetyl bromide (0.027 mL) and TEA (0.073 mL) were added to a solution of intermediate 14b (162 mg) in dry dichloromethane (2 mL) previously cooled to 0°C under a nitrogen atmosphere. The solution was stirred at 0°C for 30 minutes. The organic layer was washed with brine, dried and the solution concentrated *in vacuo* to give {2-[1-{[1-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methyl-carbamoyl}-2-(R)-(4-fluoro-2-methyl-phenyl)-piperidin-4-(S)-yl]-2-bromo-acetyl-amino]-ethyl}-carbamic acid, *tert*-butyl ester (200 mg), which was used without further purification in the next reaction.

TFA (0.2 mL) was added to a solution of this compound (200 mg) in dry dichloromethane (1.8 mL) previously cooled to 0°C under a nitrogen atmosphere. The mixture was stirred at 23°C for 3 hours, then washed with a saturated solution of sodium hydrogen carbonate (1 mL) and brine (1 mL), then dried and concentrated *in vacuo*. The residue was purified by flash chromatography (AcOEt/MeOH 8:2) to give the title compound (49 mg).

NMR (d_6 -DMSO): δ (ppm) 7.75 (bs, 1H); 7.55 (bs, 2H); 7.15 (dd, 1H); 6.8 (m, 2H); 5.55 (q, 1H); 4.7 (bm, 1H); 4.35 (dd, 1H); 3.6-2.9 (m, 6H); 2.7 (s, 3H); 2.4 (s, 3H); 2.5-2.0 (bm, 2H); 2.0-1.5 (m, 4H); 1.4 (d, 3H).

Example 13**2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-(4-methyl-2-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid, [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide hydrochloride**

5 Formaldehyde (37 % in water, 0.012 mL) was added to a solution of example 12 (49 mg) in acetonitrile (8 mL). The mixture was stirred for 30 minutes at room temperature, then sodium triacetoxyborohydride (26 mg) was added. The solution was stirred for 4 hours at 23°C and concentrated *in vacuo*. The residue was dissolved in DCM and the organic layer washed with 5% sodium hydrogen carbonate solution (10 mL) and brine, then dried and concentrated *in vacuo*. The residue was purified by flash chromatography (AcOEt/MeOH 9:1) to give 2-(R)-(4-fluoro-2-methyl-phenyl)-4-(S)-(4-methyl-2-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid, [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide (22 mg).

10 This material (22 mg) was dissolved in dry Et₂O (2.5 mL) and treated with hydrochloric acid (1M in Et₂O – 0.2 mL). The solution was stirred at 0°C for 30 minutes, then it was concentrated *in vacuo* to give the title compound (18 mg) as a white solid.

15 NMR (d₆-DMSO): δ (ppm) 10.82 (bs, 1H); 7.96 (s, 1H); 7.55 (s, 2H); 7.18 (dd, 1H); 6.86 (dd, 1H); 6.75 (dt, 1H); 5.3 (q, 1H); 4.41 (bt, 1H); 4.18 (dd, 1H); 3.9-3.4 (many bs, 6H); 3.37 (m, 1H); 2.8 (m, 1H); 2.74 (bs, 3H); 2.69 (bs, 3H); 2.3 (bs, 3H); 1.93 (m, 1H); 1.75 (q, 1H); 1.63 (bd, 1H); 1.54 (bd, 1H); 1.43 (d, 3H).

20 MS (ES/+): m/z=603 [M+H-HCl]⁺.

Examples 14a and 14b**2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(R)-(4-cyclopropyl-3-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid, 1-(3,5-bis-trifluoromethyl-benzyl)-methylamide hydrochloride (14a)****2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-(4-cyclopropyl-3-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid, 1-(3,5-bis-trifluoromethyl-benzyl)-methylamide hydrochloride (14b)**

30 TFA (2.5 mL) was added to a solution of intermediate 17 (254 mg) in anhydrous DCM (7.5 mL) previously cooled to 0°C under a nitrogen atmosphere. The solution was allowed to warm to r.t. and stirred at 23° C for 1 hour. The solution was concentrated *in vacuo* to give the crude 1-cyclopropyl-piperazine trifluoroacetate (269 mg), which was used without any further purification.

35 TEA (443 µL) and a solution of 1-cyclopropyl-piperazine trifluoroacetate (269 mg) in 1,2-dichloroethane (5 mL) were added to a solution of intermediate 10 (486 mg) in dry 1,2-dichloroethane (20 mL) under a nitrogen atmosphere. The resulting mixture was stirred at r.t. for 30 minutes, then sodium triacetoxyborohydride (334 mg) was added and the resulting mixture was stirred at 23°C for 16 hours. A 5% sodium hydrogen carbonate solution (20 mL) was added, the layers were separated and the aqueous layer was extracted with further DCM

40 (20 mL). The combined extracts were dried and concentrated *in vacuo*. The residue was purified by flash chromatography (from AcOEt to AcOEt/MeOH 95:5) to give two fractions:

-diastereoisomer 1 (106 mg – T.l.c. AcOEt/MeOH 95:5, R_f=0.18)

-diastereoisomer 2 (220 mg – T.l.c. AcOEt/MeOH 95:5, R_f=0.09).

Example 14a

A solution of diastereoisomer 1 (99 mg) in dry Et₂O (2 mL) was treated with hydrochloric acid (1M in Et₂O – 0.177 mL) at 0°C and the resulting mixture was stirred at 0°C for 30 minutes. The solution was concentrated *in vacuo* and the residue was triturated with pentane to give the title compound as a yellow solid (70 mg).

- 5 NMR (d₆-DMSO): δ (ppm) 10.66 (bs, 1H); 7.98 (bs, 1H); 7.78 (bs, 2H); 7.35 (bm, 1H); 6.99 (bm, 1H); 6.92 (bm, 1H); 5.17 (bm, 1H); 4.58 (d, 1H); 4.41 (d, 1H); 4.0-2.73 (many bm, 10H); 2.76 (s, 3H); 2.25 (s, 3H); 2.16 (bm, 2H); 1.77 (bm, 2H); 0.74 (bs, 2H); 0.65 (bs, 2H). MS (ES/+): m/z=614 [M+H-HCl]⁺.

Example 14b

- 10 A solution of diastereoisomer 2 (149 mg) in dry Et₂O (3 mL) was treated with hydrochloric acid (1M in Et₂O – 0.27 mL) at 0°C and the resulting mixture was stirred at 0°C for 30 minutes. The solution was concentrated *in vacuo* and the residue was triturated with pentane to give the title compound as a white solid (115 mg).

- 15 NMR (d₆-DMSO): δ (ppm) 11.23 (bs, 1H); 7.95 (s, 1H); 7.58 (s, 2H); 7.28 (m, 1H); 6.94 (dd, 1H); 6.82 (dt, 1H); 4.62 (d, 1H); 4.37 (d, 1H); 4.18 (bd, 1H); 4.0-3.0 (bm, 8H); 2.92 (s, 3H); 2.7 (m, 2H); 2.37 (s, 3H); 2.2-1.6 (bm, 4H); 0.72 (bd, 2H); 0.63 (bd, 2H). MS (ES/+): m/z=614 [M+H-HCl]⁺.

Example 15

- 20 4-(S)-[1-[(3,5-Bis-trifluoromethyl-benzyl)-methyl-carbamoyl]-2-(R)-(4-fluoro-2-methyl-phenyl)-piperidin-4-yl]-piperazine

- TFA (1 mL) was added to a solution of intermediate 18b (155 mg) in anhydrous DCM (5 mL). The solution was stirred at r.t. for 3 hours, then it was concentrated *in vacuo*. The residue was diluted in a saturated potassium carbonate solution (10 mL) and extracted with DCM (2 x 20 mL) and AcOEt (20 mL). The combined organic extracts were dried and concentrated *in vacuo* to give the title compound (104 mg) as an oil.

T.l.c.: AcOEt/MeOH 8:2, R_f=0.12.

IR (nujol, cm⁻¹): 1653 (C=O).

- 30 NMR (d₆-DMSO): δ (ppm) 7.94 (s, 1H); 7.59 (s, 2H); 7.22 (dd, 1H); 6.89 (dd, 1H); 6.77 (dt, 1H); 4.62 (d, 1H); 4.36 (d, 1H); 4.13 (dd, 1H); 3.44 (dt, 1H); 3.3 (m, 1H); 2.9 (s, 3H); 2.67 (m, 1H); 2.65 (m, 4H); 2.4 (bm, 4H); 2.34 (s, 3H); 1.86 (bd, 1H); 1.77 (bd, 1H); 1.6 (dq, 1H); 1.34 (q, 1H).

MS (ES/+): m/z=561 [MH]⁺.

35 Example 16

2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-(1-methanesulfonyl-piperazin-1-yl)-piperidine-1-carboxylic acid, 1-(3,5-bis-trifluoromethyl-benzyl)-methanamide

Methanesulfonyl chloride (11.8 μL) was added to a solution of example 15 (80 mg) and TEA (40 μL) in anhydrous DCM (3 mL) previously cooled to 0°C under a Nitrogen atmosphere.

- 40 The solution was stirred at 0°C for 4 hours, then it was washed with saturated sodium hydrogen carbonate solution (5 mL). The layers were separated and the organic phase was extracted with further DCM (3 x 5 mL). The combined organic extracts were dried and concentrated *in vacuo* to a residue, which was purified by flash chromatography (AcOEt/MeOH 9:1) to give the title compound (60 mg) as a colourless oil.

T.l.c.: AcOEt/MeOH 9:1, R_f=0.27.

NMR (d₆-DMSO): δ (ppm) 7.93 (s, 1H); 7.59 (s, 2H); 7.23 (dd, 1H); 6.89 (dd, 1H); 6.77 (dt, 1H); 4.62 (d, 1H); 4.36 (d, 1H); 4.14 (dd, 1H); 3.46 (m, 1H); 3.3 (m, 1H); 3.04 (m, 4H); 2.9 (s, 3H); 2.83 (s, 3H); 2.67 (t, 1H); 2.5 (m, 4H); 2.34 (s, 3H); 1.9-1.75 (m, 2H); 1.65 (m, 1H); 1.38 (m, 1H).

MS (ES/+): m/z=639 [MH]⁺.

Example 17

2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-(1-methanesulfonyl-piperazin-1-yl)-piperidine-1-carboxylic acid, 1-(3,5-bis-trifluoromethyl-benzyl)-methylamide hydrochloride

A solution of example 16 (58 mg) in dry Et₂O (2 mL) was treated with hydrochloric acid (1M in Et₂O – 0.1 mL) at 0°C and the resulting mixture was stirred at 0°C for 30 minutes. The solution was concentrated *in vacuo* and the residue was triturated with pentane to give the title compound as a white solid (53 mg).

NMR (d₆-DMSO): δ (ppm) 10.09 (bs, 1H); 7.96 (bs, 1H); 7.61 (bs, 2H); 7.27 (m, 1H); 6.96 (m, 1H); 6.84 (m, 1H); 4.64 (d, 1H); 4.37 (d, 1H); 4.22 (d, 1H); 3.8-3.5 (m, 2H); 3.5-2.9 (m, 8H); 3.02 (s, 3H); 2.94 (s, 3H); 2.76 (m, 1H); 2.38 (m, 3H); 2.17 (m, 2H); 1.88 (m, 1H); 1.69 (m, 1H).

MS (ES/+): m/z=639 [MH-HCl]⁺.

Example 18

2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-(1-methanesulfonyl-piperazin-1-yl)-piperidine-1-carboxylic acid, 1-[(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide

A solution of intermediate 4a (160 mg), N-*tert*-butoxycarbonyl-piperazine (60 mg) and sodium triacetoxyborohydride (100 mg) in dry 1,2-dichloroethane (12 mL) was stirred at 23°C for 24 hours under a nitrogen atmosphere. The solution was washed with a 5% sodium hydrogen carbonate solution (20 mL) and brine (20 mL). The organic layer was dried and concentrated *in vacuo* to a residue, which was purified by flash chromatography (CH/AcOEt from 1:1 to 3:7) to give:

2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(R)-[(4-*tert*-butoxycarbonyl)-piperazin-1-yl]-piperidine-1-carboxylic acid, [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide (74 mg – T.l.c.: CH/AcOEt 1:1, R_f=0.35 hereinafter compound 1)

–2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-[(4-*tert*-butoxycarbonyl)-piperazin-1-yl]-piperidine-1-carboxylic acid, [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide (48 mg – T.l.c.: CH/AcOEt 1:1, R_f=0.19 hereinafter compound 2)

Trifluoroacetic acid (1 mL) was added drop-wise at 0°C to a solution of compound 2 (48 mg) in dry DCM (3 mL). The solution was stirred for 1 hour at the same temperature and for 1 hour at r.t.. Then the solvent was removed *in vacuo* and the crude dissolved in AcOEt (5 mL). The resulting solution was washed with a saturated potassium carbonate solution and dried. After concentration *in vacuo*, the crude 2-(R)-(4-fluoro-2-methyl-phenyl)-4-(S)-piperazin-1-yl-piperidine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide (18 mg) was obtained.

Methanesulfonyl chloride (6 μL) and TEA (20 μL) were added to a solution of this intermediate (40 mg) in anhydrous DCM (3 mL) previously cooled to 0°C under a Nitrogen

atmosphere. The solution was stirred at 0°C for 4 hours, then it was washed with saturated sodium hydrogen carbonate solution (5 mL). The layers were separated and the organic phase was extracted with further DCM (3 x 5 mL). The combined organic extracts were dried and concentrated *in vacuo* to a residue, which was purified by flash chromatography (AcOEt/CH 94:6) to give the title compound (26 mg) as a colourless oil.

T.l.c.: AcOEt/CH 96:4, R_f=0.15.

NMR (d₆-DMSO): δ (ppm) 7.98 (s, 1H); 7.67 (s, 2H); 7.16 (dd, 1H); 6.89 (dd, 1H); 6.74 (dt, 1H); 5.32 (q, 1H); 4.13 (dd, 1H); 3.39 (m, 1H); 3.3 (m, 1H); 3.04 (m, 4H); 2.82 (s, 3H); 2.7 (s, 4H); 2.56 (m, 4H); 2.33 (s, 3H); 1.9-1.4 (m, 4H); 1.45 (d, 3H).

MS (ES/+): m/z=653 [MH]⁺.

Example 19

2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-(1-methanesulfonyl-piperazin-1-yl)-piperidine-1-carboxylic acid, 1-[(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methanamide
hydrochloride

A solution of example 18 (24.7 mg) in dry Et₂O (1.5 mL) was treated with hydrochloric acid (1M in Et₂O – 0.042 mL) at 0°C and the resulting mixture was stirred at 0°C for 30 minutes. The solution was concentrated *in vacuo* and the residue was triturated with pentane to give the title compound as a white solid (22 mg).


NMR (d₆-DMSO): δ (ppm) 10.62 (bs, 1H); 7.98 (s, 1H); 7.67 (s, 2H); 7.21 (dt, 1H); 6.94 (dd, 1H); 6.82 (dt, 1H); 5.3 (q, 1H); 4.18 (dd, 1H); 3.8-3.45 (m, 5H); 3.3-3.1 (m, 5H); 2.99 (s, 3H); 2.73 (s, 3H); 2.7 (t, 1H); 2.35 (s, 3H); 2.2 (m, 2H); 1.9-1.7 (m, 2H); 1.46 (d, 3H).

MS (ES/+): m/z=653 [MH-HCl]⁺.

The application of which this description and claims forms part may be used as a basis for priority in respect of any subsequent application. The claims of such subsequent application may be directed to any feature or combination of features described herein. They may take the form of product, composition, process, or use claims and may include, by way of example and without limitation, the following claims.

Claims

1. A compound of formula (I)



wherein

R represents halogen or C₁₋₄ alkyl;

R₁ represents C₁₋₄ alkyl;

R₂ represents hydrogen or C₁₋₄ alkyl;

R₃ represents hydrogen, or C₁₋₄ alkyl;

R₄ represents trifluoromethyl, C₁₋₄ alkyl, C₁₋₄ alkoxy, trifluoromethoxy or halogen;

R₅ represents hydrogen, C₁₋₄ alkyl, C₃₋₇ cycloalkyl or S(O)₂R₆;

R₆ represents C₁₋₄ alkyl or C₃₋₇ cycloalkyl;

m is zero or an integer from 1 to 3;

n is an integer from 1 to 3;

p is an integer from 1 to 2;

X and Y are independently C(O) or CH₂;

provided that

i) X and Y are not both C(O) and

ii) when X and Y are both CH₂, R₅ is not hydrogen or C₁₋₄ alkyl ;

and pharmaceutically acceptable salts and solvates thereof.

2. A compound selected from

2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(R)-(3-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid, (3,5-bis-trifluoromethyl-benzyl)-methylamide;

2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-(3-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid, (3,5-bis-trifluoromethyl-benzyl)-methylamide;

2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(R)-(4-methyl-3-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid, 1-(3,5-bis-trifluoromethyl-benzyl)-methylamide;

2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-(4-methyl-3-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid, 1-(3,5-bis-trifluoromethyl-benzyl)-methylamide;

2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-(4-methyl-3-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid, [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide;

2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(R)-(2-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid
 (3,5-bis-trifluoromethyl-benzyl)-methylamide;
 2-(4-Fluoro-2-methyl-phenyl)-4-(S)-(2-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid,
 (3,5-bis-trifluoromethyl-benzyl)-methylamide;
 5 2-(4-Fluoro-2-methyl-phenyl)-4-(S)-(2-oxo-piperazin-1-yl)-piperidine-1-carboxylic acid,
 (3,5-bis-trifluoromethyl-benzyl)-methylamide;
 2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-(2-oxo-4-methyl-piperazin-1-yl)-piperidine-1-
 carboxylic acid, (3,5-bis-trifluoromethyl-benzyl)-methylamide;
 2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-(4-methyl-2-oxo-piperazin-1-yl)-piperidine-1-
 10 carboxylic acid, [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide;
 2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-(4-methyl-2-oxo-piperazin-1-yl)-piperidine-1-
 carboxylic acid, [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide;
 2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(R)-(4-cyclopropyl-3-oxo-piperazin-1-yl)-piperidine-1-
 carboxylic acid, 1-(3,5-bis-trifluoromethyl-benzyl)-methylamide;
 15 2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-(4-cyclopropyl-3-oxo-piperazin-1-yl)-piperidine-1-
 carboxylic acid, 1-(3,5-bis-trifluoromethyl-benzyl)-methylamide;
 4-(S)-[1-[(3,5-Bis-trifluoromethyl-benzyl)-methyl-carbamoyl]-2-(R)-(4-fluoro-2-methyl-
 phenyl)-piperidin-4-yl]-piperazine;
 2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-(1-methanesulfonyl-piperazin-1-yl)-piperidine-1-
 20 carboxylic acid, 1-(3,5-bis-trifluoromethyl-benzyl)-methylamide;
 2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-(1-methanesulfonyl-piperazin-1-yl)-piperidine-1-
 carboxylic acid, 1-[(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide;
 and pharmaceutically acceptable salts (e.g. hydrochloride, methanesulphonate, sulphate, p-
 toluensulphonate), solvates thereof.

25

3. A compound as claimed in claim 1 or 2 for use in therapy.


4. The use of a compound as claimed in claim 1 or 2 in the preparation of a medicament
 for use in the treatment of conditions mediated by tachykinins, including substance P and
 30 other neurokinins.

5. The use of a compound as claimed in claim 1 or 2 for use in the treatment of
 conditions mediated by tachykinins, including substance P and other neurokinins.


35 6. A pharmaceutical composition comprising a compound as claimed in claim 1 or 2 in
 admixture with one or more pharmaceutically acceptable carriers or excipients.

7. A method for the treatment of a mammal, including man, in particular in the
 treatment of conditions mediated by tachykinins, including substance P and other
 40 neurokinins, comprising administration of an effective amount of a compound as claimed in
 claim 1 or 2.

a) reacting a compound of formula (II),



b) cyclisation of a compound of formula (VII),




followed where necessary or desired by one or more of the following steps:

- i) removal of any protecting group;
- ii) isolation of the compound as a salt or a solvate thereof;
- iii) separation of a compound of formula(I) or derivative thereof into the enantiomers thereof.

Abstract

The present invention relates to piperidine derivatives of formula (I)



wherein

R represents halogen or C₁₋₄ alkyl;

R₁ represents C₁₋₄ alkyl;

R₂ represents hydrogen or C₁₋₄ alkyl;

10 R₃ represents hydrogen, or C₁₋₄ alkyl;

R₄ represents trifluoromethyl, C₁₋₄ alkyl, C₁₋₄ alkoxy, trifluoromethoxy or halogen;

R₅ represents hydrogen, C₁₋₄ alkyl, C₃₋₇ cycloalkyl or S(O)₂R₆;

R₆ represents C₁₋₄ alkyl or C₃₋₇ cycloalkyl;

m is zero or an integer from 1 to 3;

15 n is an integer from 1 to 3;

p is an integer from 1 to 2;

X and Y are independently C(O) or CH₂;

provided that

i) X and Y are not both C(O) and

20 ii) when X and Y are both CH₂, R₅ is not hydrogen or C₁₋₄ alkyl ;

and pharmaceutically acceptable salts and solvates thereof, the process for their preparation and their use in the treatment of condition mediated by tachykinins.